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Abstract 
Natural macrocyclic peptides isolated from marine metabolites have shown 
interesting biological activities, including anticancer properties. In addition, they are 
highly pre-organized for metal inclusion due to their structural features, such as the 
presence of a cavity with perfectly located oxygen and nitrogen donors within the 
macrocyclic structure. This thesis pertains to the development of a synthetic approach 
towards the synthesis of natural macrocyclic structures. These macrocyclic peptides 
are made up of four oxazole rings connected by amide bonds with functionalized side 
chains. A synthetic strategy for the synthesis of natural peptide-derived macrocyclic 
analogues was developed using solution phase peptide synthesis. The synthesis of the 
tetraoxazole macrocycle is described in more detail where the synthesis started with 
the formation of a dipeptide by coupling two amino acids, followed by oxazole ring 
formation, and subsequent formation of the di-, tri-, and tetraoxazole peptide. All of 
the peptide bonds were obtained using O-(benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HBTU) or 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCl) with 
hydroxybenzotriazole (HOBt) with the base N,N-diisopropylethylamine (DIEA). 
Finally, macrocyclization of the linear unprotected tetraoxazole gave the macrocyclic 
structure. The macrocyclization was achieved efficiently by using (ethyl 
cyano(hydroxyimino)acetato)-tri-(1-pyrrolidinyl)-phosphonium hexafluorophosphate 
(PyOxim) as a coupling reagent under very dilute conditions. All structures were 
analyzed by 1H and 13C NMR. With the structural similarities to the macrocyclic 
peptides isolated from marine sources, this tetraoxazole macrocyclic peptide might be 
used as a chelating agent. 
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Chapter 1- Introduction 
1.1 Overview  
Macrocyclic peptides, in a variety of sizes and shapes, have been isolated as secondary 
metabolites from natural sources such as bacteria, fungi, plants, and marine sources, and 
many have been proven to possess interesting biological properties. During studies 
conducted in the 1970s, several secondary metabolites were isolated from marine 
organisms with differing properties, including antitumor, antibiotic, and cytotoxic 
activities.1,2 
The major drawback for studying the chemistry of the natural metabolites is the low 
availability of these compounds as only a small amount is available through expensive 
extraction processes from their natural origins. Because of the unique properties and the 
low availability of these metabolites, synthetic routes to the natural products and their 
model systems were researched to study and evaluate their pharmacological properties.3  
1.2 Biological active macrocyclic peptides 
1.2.1 Cyclosporine A  
Macrocyclic peptides have been used in medicine for decades and have made significant 
improvements to the treatment of several diseases. Cyclosporine A is one of the natural 
cyclic peptides that have pharmacological properties. It is used as an immunosuppressant 
drug in organ transplantation in order to prevent the risk of organ rejection. It is isolated 
from the metabolites produced by Tolypocladium inflatum, and has seven N-methyl 
amino acids (Figure 1).4,5 
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Figure 1: Structure of cyclosporine A.4 
 
It was reported that cyclosporine A has one exocyclic and three endocyclic hydrogen 
bonds that limit the conformational freedom. It was also found that in CDCl3 the 
hydrophobic peptide forms a twisted β-sheet with one of the N-methylated amide bonds. 
Nevertheless, it can adopt six different conformations in polar solvents such as methanol 
or water.6 
In addition, when the size of a cyclic peptide increases, the conformational flexibility also 
rises resulting in a variety of rapidly interconverting structures. In order to restrict the 
conformation of the cyclic peptide, nature incorporates uncommon amino acids and 
constraints into the cyclic peptide in order to reduce the conformational degrees of 
freedom. In fact, when an amino acid adjusts to another, they can find ways to combine 
together to form a heterocyclic ring that is often a very active constraint. For example, the 
cyclooctapeptide -[L-Thr-D-Val-L-Cys-L-lle]-2 depicted in Figure 2 is flexible and can 
adopt a variety of conformations.1 
N
N
N N
H
H
N
N
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N
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N
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O
O
O
O
O
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O
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Figure 2: Structure of the cyclooctapeptide -[L-Thr-D-Val-L-Cys-L-lle]-2.1 
 
 
However, after intramolecular condensation of the threonine and cysteine side chains 
with the neighboring carbonyl groups, in the peptide sequence, it forms oxazoline and 
thiazole rings respectively, as shown for ascidiacyclamide in Figure 3. In this case, it 
only produces a single saddle shaped conformation. This conformation was confirmed via 
NMR spectroscopy as well as X-ray crystallography.6 
 
Figure 3: Structure of ascidiacyclamide.1 
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There are various biologically active macrocyclic peptides that have heterocyclic 
moieties in their core structure such as oxazolines, oxazoles, thiazolines, and thiazoles 
isolated from natural sources. These five membered heterocyclic rings are formed from 
the condensation of serine, threonine, and cysteine side chains with the preceding 
carbonyl groups in the peptide sequence.7 
Indeed, all these moieties introduce conformational restrictions in the macrocyclic 
peptides making them a unique class of molecules. Some of the cyclic peptides that 
contain these conformational constraints have biological properties which include 
enzyme inhibition, antibiotic activity, antitumor activity, or anti-inflammatory activity.6 
However, the biological activity of these macrocycles in the marine organism is still 
unresolved. Due to the size and the conformation of these macrocycles, as well as the 
nature of functional groups, it might allow these macrocyclic peptides to function as 
metal complexation and transport agents in vivo.8 
 
1.2.2 Ascidiacyclamide 
Ascidiacyclamide was isolated from Lissoclinum patella, and it is a 24-membered 
azacrown-8 macrocycle (Figure 3). It consists of two thiazole and two oxazoline rings 
connected by amide bonds with unique biological properties, such as antitumor activity. 
In addition, the macrocyclic peptide can be called a pseudo-octapeptide since its 
heterocyclic rings are derived from the condensation of two amino acid residues.8 
It has been observed that organisms like ascidians, known as sea squirts, can concentrate 
metals, including copper, up to a concentration ten thousand times higher than that found 
in the local marine environment. In fact, Cu(II) ions can be observed in non-polar 
fractions of the sea squirt, which suggests that Cu(II) ions are complexed by organic 
molecules, such as the cyclic peptide ascidiacyclamide. The macrocyclic peptides are 
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most likely produced to coordinate with Cu(II) ions, and these Cu(II) complexes might be 
involved in the ascidian’s metabolism.8 
The saddle shaped conformation of ascidiacyclamide can contain two copper ions. These 
two copper ions are able to capture CO2 to form a carbonate-bridged dinuclear Cu(II) 
complex. The Cu(II) ions are coordinated to three nitrogen donors; two from the 
heterocyclic ring and a third originating from a deprotonated amide. The coordination 
sphere of Cu(II) is completed by one molecule of water each as shown in Figure 4.6,9 
 
 
Figure 4: Structure of ascidiacyclamide complex with copper(II).9 
 
 
The heterocyclic rings afford two of the three nitrogen donors, thus, they affect the 
coordination chemistry of the macrocyclic peptides and the complex stabilities. This 
metal complex of a marine cyclic peptide might be involved in hydrolysis and transport 
of CO2 in the ascidian’s metabolism. Other possible applications of this complexation are 
Cu(II) detoxification, storage or transport.8  
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1.2.3 Structural features of cyclic pseudo-octapeptides  
The structural features of cyclic pseudo-octapeptides were investigated in order to 
explain the coordination chemistry of these cyclic peptides. Indeed, the conformations of 
the marine macrocyclic peptides that incorporate heterocyclic rings were studied in both 
solution as well as solid phases. Analysis of the solid phase of these macrocycles was 
carried out using X-ray crystallography while 1H and 13C NMR spectroscopy were used 
for analysis of the structures in solution. These studies afforded valuable information that 
explains how the complexation might influence the reactivity and the biology of these 
metabolites.8 
There are many factors that can affect the structure of cyclic pseudo-peptides, such as the 
amino acid residues that connect the heterocyclic rings, the configuration of amino acids 
(R or S), and the nature of incorporated heterocyclic rings. The macrocyclic peptides 
adopt inflexible structures when the macrocyclic ring closes. Furthermore, incorporation 
of unsaturated heterocycles lowers the flexibility of the macrocyclic peptides and the 
planarity of the heterocycle is increased to the adjacent peptide group.8 
The cyclic pseudo-octapeptides can adopt a variety of conformations depending on the 
connecting amino acids.10 As aforementioned, symmetrical peptides like 
ascidiacyclamide take on a saddle-shaped conformation also referred to as a square 
conformation, where the oxazoline and thiazole rings are placed alternately at each corner 
of the rectangular ring, and the eight nitrogen atoms point toward the inside of the 
molecular structure. Conversely, asymmetrical peptides such as patellamide D (Figure 
5), which is another natural cyclic peptide isolated from Lissoclinum patella, adopt a 
figure eight conformation as shown in the Figure 6.  
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This conformation is stabilized by intramolecular hydrogen bonds as well as by π-
stacking of its heterocyclic rings. This conformation is stabilized by two trans-annular N-
H….O=C (amide) and two trans-annular N-H….Ooxa  (oxazoline ring) hydrogen bonds; 
see Figure 7 for nomenclature. Moreover, the nitrogen atom in the oxazoline rings point 
toward the outside of the macrocyclic peptide in this conformation.11,12  
 
 
Figure 5: Structure of patellamide D.12  
 
Figure 6: Conformations of cyclic pseudo-octapeptides (ascidiacyclamide and 
patellamide): square and figure eight.12 
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Usually, all of the protons from the amide bonds point towards the center of the 
macrocycle whereas the carbonyl groups point towards the outside of the macrocyclic 
peptide. In addition, the amino acid side chains adopt axial positions. In the case where 
all the amino acid residues that connect the heterocycles have identical configuration (L- 
or D-), all the amino acid residues face the same side of the macrocycle. On the other 
hand, if the cyclic pseudo-peptides are built up from D- and L-amino acids, the 
macrocyclic peptides can exhibit an alternating stereochemistry in the linkers like 
ascidiacyclamide. Furthermore, the incorporation of oxazoline rings produces an almost 
coplanar structure of the heterocyclic moieties of the macrocyclic peptides whereas those 
peptides that contain oxazole would have a cone-like structure.11  
 
 
Figure 7: Nomenclature of the heterocyclic blocks of the macrocycle.11 
 
1.2.4 Westiellamide  
Westiellamide is a cyclic pseudo-hexapeptide isolated from the ascidian Lissoclinum 
bistratum. As in the bigger 24-membered azacrown-8 macrocycles, westiellamide, an 18-
membered azacrown-6 macrocycle, is highly preorganized for metal complexation. This 
compound has three oxazoline rings that are connected by amide bonds in a preorganized 
arrangement (Figure 8).13,14 
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Based on the study by Comba and co-workers15, westiellamide forms stable mononuclear 
and dinuclear Cu(II) complexes. The formation of complexes involves metal-ion-assisted 
deprotonation of amide bonds, providing nitrogen donors. Moreover, in mononuclear 
complexes, Cu(II) ion prefers to bind to a Nheterocycle-Namide-Nheterocycle binding site. 
However, in the methoxide or hydroxide-bridged dinuclear complexes, the second Cu(II) 
ion is coordinated to a Namide-Nheterocycle-Namide binding site. 
 
 
Figure 8: Structure of Westiellamide.13 
  
Furthermore, systematic metal-ion-binding studies with westiellamide have reported the 
affinity of Ag(I). Initial studies on the metal complexation of westiellamide were 
conducted by Wipf and co-workers who described a unique Ag4 cluster complex with 
westiellamide (Figure 9).16 In fact, three Ag(I) ions are organized in a pseudo trigonal 
arrangement around the central silver ion Ag(I)  and are bordered on two sides by two 
macrocycles.  The central silver ion Ag(I)  is coordinated in an octahedral arrangement 
by the carbonyl oxygen atoms of the two westiellamide macrocycles.   
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1.2.5 Structural feature of cyclic pseudo-hexapeptide 
The configuration of westiellamide is S where the L-valine’s side chains are all on one 
side of the macrocyclic peptide, and the amide and heterocyclic nitrogen donor atoms 
point toward the inside of the macrocycle.13 Moreover, the metal free macrocycle 
westiellamide, which is a symmetrical cyclic peptide, adopts a triangular configuration. 
Indeed, the heterocyclic nitrogen atoms as well as the amide hydrogen atoms point 
towards the inside of the macrocycle. Nevertheless, this conformation is twisted in the 
silver cluster. The carbonyl groups of westiellamide are rotated towards the inside of the 
macrocycle in order to coordinate with the central Ag(I) ion, and at the same time rotate 
the amide nitrogen atoms towards the outside of the westiellamide. The x-ray structure 
shows an unusual feature of the sandwich complex where the central Ag(I) is coordinated 
octahedrally by carbonyl oxygen atoms of the two-westiellamide macrocycles.17 
 
 
Figure 9: X-ray structure of the silver(I) complex of westiellamide.8 
 
1.2.6 Telomestatin 
Telomestatin is a natural product that has been isolated from Streptomyces anulatus 
3533-SV4, whose structure is made up of a macrocycle containing linkage of two methyl 
	  	   11	  
oxazoles, five oxazole rings, and one chiral thiazoline ring as shown in the Figure 10. 
Telomestatin is one of the most potent telomerase inhibitors reported to date. Due to the 
high affinity of telomestatin for intramolecular G-quadruplex structures, it can inhibit the 
cell growth in cancer cells.18 Telomestatin is involved in the selective binding of G-
quadruplex structures, and the high affinity and specificity of telomestatin for G-
quadruplex is justified by its size as well as shape complementarity with G-tetrads of G-
quadruplex DNA.19  
It was also found that telomestatin has the affinity to coordinate with cations such as K+ 
and Na+, and this feature could affect its binding to G-quadruplex DNA.20 
 
Figure 10: Structure of Telomestatin.18 
 
One main drawback of telomestatin is the difficulty in obtaining it from natural sources. 
The amount that has been isolated from the bacteria is very low. In addition, the total 
synthesis of telomestatin was described in a study conducted by Takahashi et al., (2006) 
however, their method is not sufficient for large-scale synthesis, and is not suitable for 
the synthesis of derivatives. 21   
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1.3 Metal ion coordination to cyclic peptides in nature 
Many of the marine macrocycles such as ascidiacyclamide, and westiellamide consist of 
a macrocyclic cavity with polar functional groups. This together with the capacity of 
ascidians to concentrate metal ions suggests that the macrocycles are made to bind with 
metal ions. The geometric arrangement of the functional groups in the macrocyclic 
peptides, the set of nitrogen donors in the macrocycles, as well as the size of these 
compounds suggests that their biological functions are to coordinate with metal ions. The 
purpose of this macrocyclic complexation might be responsible for either metal transport, 
biological assembly of the metabolites, or catalysis.8,15 
 
1.4 Advantages of macrocyclic peptides over linear peptides 
Peptides show several advantages as components of drugs, such as low toxicity, since 
they are made up of amino acids. However, linear peptides adopt a variety of 
conformations in solution. This conformational flexibility of linear peptides often leads to 
poor selectively against biological targets.22 In addition, linear peptides are highly 
degraded by peptidases, which leads to low bioavailability. One method to reduce the 
flexibility of peptides, and instability to peptidases, is the cyclization of the linear 
peptides. Cyclization of a linear peptide is a useful strategy to limit the conformational 
freedom thereby increasing the binding affinity as well as the selectivity for the 
biological target.23 
The hydrophobic side chains of macrocyclic peptides afford a hydrophobic surface that 
shields or protects their cleavable amide bonds from degradation by peptidases. This 
hydrophobic surface might also facilitate their penetration into cell membranes. 
Therefore, increasing resistance to degradation by peptidases leads to longer lifetimes in 
biological systems. Furthermore, because the macrocyclic peptides impose limitations to 
conformational flexibility, they are capable of better selective interactions with 
bioreceptors, compared to the flexible linear peptides. Thus, the macrocyclic peptides are 
usually less toxic than the linear peptides.6 
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1.5 Synthetic routes to peptide-derived macrocycles 
In general, the synthesis that is used to create these types of peptide-derived macrocycles 
is made up of three parts. First, the heterocyclic building block, made up of an amino acid 
linker and a heterocyclic ring, is synthesized. Second, convergent or stepwise coupling of 
the building blocks is achieved in order to obtain the desired linear peptide, with 
heterocyclic rings. The last step is the macrocyclization under dilute conditions to avoid 
intermolecular coupling and induce the preferred intramacrocyclization.24,25,3  
Symmetrical macrocyclic structures can be created by forming dimers and tetramers, 
from the oxazole building block, followed by macrocyclization. Asymmetrical 
macrocyclic structures might need the synthesis of a different linear sequence, with a 
subsequent macrocyclization.26 
 
1.6 Synthesis of macrocyclic peptides  
Depending on the amino acid’s functional group, there are four different strategies that 
can be used to transform a peptide into a macrocycle. The first of these strategies is head-
to-tail cyclization where the amide bond forms between the carboxyl and the amino 
groups at the C- and N-terminus. The second strategy is a side chain-to-tail cyclization 
where the peptide bond forms between the amino group at the N-terminus and the 
carboxyl group of the side chain.  The third strategy is a head-to-side chain cyclization, 
where peptide bond formation is achieved with the amino group of the side chain and the 
carboxylic group of the C-terminus. Finally, there is the side-chain-to-side-chain 
cyclization where a disulfide bond or bridge forms from the two cysteine residues as seen 
in Figure 11.27 Scientists have used each of these methods to form macrocyclic peptides, 
but the two most commonly employed methods are head-to-tail and side-chain-to-side-
chain cyclization.27 The former is the most common strategy used for cyclizing peptides 
in solution phase peptide synthesis. In addition, cyclization in solution phase is faster and 
provides the final cyclic peptide in a high yield.22 
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Figure 11: Four different ways to constrain a peptide into a macrocycle (figure adapted 
from reference 26). 
It is preferred that macrocyclizations be done under high dilution in order to minimize the 
intermolecular side reactions, giving rise to oligomers and polymers of the peptide. 
Furthermore, the cyclization of a peptide depends on the ability of the linear peptide to 
prearrange its two reactive terminals within close proximity of one another. The 
prearrangement leads to efficient macrocyclization with fewer side-reactions resulting 
from intermolecular reactions.27 
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1.7 Objective 
Macrocyclic peptides that have been isolated from marine sources have shown interesting 
metal complexation patterns. The structures of these macrocycles are highly preorganized 
for optimal metal ion complexation, in terms of their ring structure, the size of the 
macrocyclic peptide, and the set of the amide bonds as well as the nitrogen donor atoms 
in the heterocyclic rings.  
This thesis deals with the synthesis of new tetraoxazole macrocyclic peptides (Figure 12) 
which mimic the structure of the natural macrocycles. The macrocyclic peptides designed 
are analogues of the marine natural products, which contain four oxazole rings connected 
by amide bonds and functionalized with hydrophobic amino acid residues, such as tert-
butyldimethylsilyl (TBS) or tert-butyl (t-Bu) groups.  This thesis presents the design as 
well as the methodology to create these macrocyclic peptides through solution phase 
peptide synthesis.  
In addition, towards the synthesis of these macrocyclic peptides, new synthetic 
methodologies will be developed including the use of silyl-protected alcohols for 
cyclodehydration reactions, as well as the synthesis of linear di-, tri-, and tetraoxazole 
peptides. 
Figure 12: The tetraoxazole macrocyclic peptides. 
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Chapter 2- Result and discussion  
2.1 Retrosynthetic approach towards amino acid-derived 
tetraoxazole macrocyclic structures 
The retrosynthetic analysis of the target molecule (tetraoxazole macrocyclic peptide), 
shown in Scheme 1, involves a convergent synthesis using a solution phase peptide 
approach.  Because the desired compound is symmetric, tetraoxazole can be made using a 
short synthetic route. Once the monooxazole is obtained, from the cyclodehydration and 
oxidation of a diserine, the dioxazole can be produced by dividing the amount of the 
monooxazole in half. One half of the monooxazole can be used to deprotect the N-
terminus and the other portion to deprotect the C-terminus, thus allowing for the selective 
coupling of these peptides to get the dioxazole. The three steps can be repeated in order 
to obtain the tetraoxazole. 
The desired octapeptide (tetraoxazole) macrocycle was synthesized by a head-to-tail 
peptide coupling of the linear tetraoxazole precursor at very dilute concentrations. The 
concentration is critical in the synthesis of macrocyclic peptide to minimize the formation 
of oligomers. The linear tetraoxazole was generated by full deprotection of the protected 
tetraoxazole peptide. The tetraoxazole was obtained by coupling two dioxazoles, and the 
dioxazole precursor was synthesized by coupling two monooxazoles. In addition, 
monooxazole was generated by cyclodehydration followed by oxidation of the dipeptide, 
which was generated by coupling two protected L-serines where PG is the abbreviation 
used for used for protecting group. Thus, three protecting groups were used in the 
synthesis of tetraoxazole macrocyclic peptide: fluorenylmethyloxycarbonyl (Fmoc) group 
to protect the amine; methyl ester (OMe) group to protect the acid; and TBS group to 
protect the hydroxyl group of Ser. 
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Scheme 1:	   Retrosynthesis of the tetraoxazole macrocyclic peptide containing the TBS 
protected L-serine residue. 
 
It is known that the Fmoc group can be removed by using AlCl3 and N,N-dimethylaniline 
(DMA) to get the free amine.28 Methyl ester hydrolysis can be achieved by using NaOH 
and CaCl2 in i-PrOH/H2O to give the free acid.29  
It was preferred to use solution phase peptide synthesis because the intermediates can be 
isolated and characterized after each step. It is easy to detect the products of side 
reactions and remove unwanted by-products prior to the next reaction.30 In contrast, solid 
phase peptide synthesis (SPPS) does not allow for immediate analysis of the intermediate 
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peptides because the peptide is attached to an insoluble polymer. Solution phase peptide 
synthesis is mostly used for large-scale peptide synthesis whereas SPPS is limited to the 
milligram scale. In addition, the synthesis of peptides made up of unusual amino acids 
such as oxazoline and oxazole, and the synthesis of cyclic peptides can be achieved 
through solution synthesis.30,31  
2.2 Preliminary synthetic studies towards the tetraoxazole 
macrocyclic peptide using a Boc protecting group 
2.2.1 Protecting the side-chain of L-serine with TBS (synthesis 
of Boc-Ser-OH(O-TBS))  
The synthesis of the tetraoxazole macrocyclic peptide requires the coupling reaction of 
several amino acid subunits, and in order to avoid side reactions, the amino acid side-
chain should be protected. The hydroxyl group of the side chain of L-serine can be 
protected as a silyl ether. The TBS group was chosen to protect the hydroxyl group 
because it is stable in alkaline solutions which make it ideal for subsequent reactions that 
need basic conditions. In addition, to the best of my knowledge, there are no reports on 
macrocyclic peptides where the side chains are protected with TBS groups. Hence, it was 
of interest to study the characteristics of this macrocycle such as complexation with metal 
ions. The protection can be accomplished by using TBSCl as a reagent with imidazole as 
a catalyst in DMF (Scheme 1).32,33 The synthesis of Boc-Ser-OH(O-TBS) (1) was 
achieved by adding TBSCl and imidazole to a solution of Boc-L-Ser in DMF at 0 0C-rt 
for 24 h. The Boc-Ser-OH(O-TBS) was obtained as a colorless oil in 50% yield. The 
structure was confirmed by 1H NMR and 13C NMR (see Appendices 1 and 2).  
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Scheme 2:	  Synthesis of Boc-Ser-OH(O-TBS).	  
 
2.2.2 Synthesis of the protected dipeptide Boc-Ser(O-TBS)-Ser-
OMe 
The protected dipeptide Boc-Ser(O-TBS)-Ser-OMe was obtained by coupling the free 
acid Boc-Ser-OH(O-TBS) with the amine HCl.H2N-L-Ser-OMe. The coupling reagent O-
(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) was 
used in order to facilitate the peptide bound formation in the coupling reaction because it 
is fast, complete, free of racemization, and proceeds with minimal side reactions.34,35 This 
reagent reacts with the carboxylic acid to form an active ester that can react with the free 
amine to form the amide bond. Furthermore, HBTU reacts with amino groups, forming 
tetramethylguanidinium derivatives. Therefore, permanent blocking of the N- terminal 
amino group can occur when HBTU is added directly to the amino compound. This 
blocking can be avoided by activating the amino acid to be coupled with the coupling 
reagent before adding the amino acid with a free amino group.36 
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Utilizing the free acid Boc-Ser-OH(O-TBS) (1), the amine as a salt HCl.H2N-L-Ser-OMe, 
HBTU and N,N-diisopropylethylamine (DIEA) as a base, the dipeptide Boc-Ser(O-TBS)-
Ser-OMe (2) was synthesized in DCM as shown in the Scheme 3.37 The reaction was 
monitored via TLC, and upon completion, the reaction was worked up by an acid-base 
extraction. The crude dipeptide was crystallized with hot hexane to give the pure 
dipeptide Boc-Ser(O-TBS)-Ser-OMe (2)  as a yellow solid in 60% yield. The structure of 
the pure dipeptide was confirmed by 1H and 13C NMR (see Appendices 3 and 4).    
 
 
Scheme 3:	  Synthesis of Boc-Ser(O-TBS)-Ser-OMe.	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and TBS groups on the dipeptide was evaluated since both of the protecting groups are 
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literature, a Boc group can be selectively removed in the presence of TBS ether using 
saturated HCl in either 1,4 dioxane or ethyl acetate without affecting the TBS group in 
the Boc-protected peptide, Boc-Leu-Tyr(TBS)-OMe. However, when the experiment was 
carried out using 0.2 mmol of the dipeptide (2) in 4 M HCl in dioxane (16 mmol),39 both 
of the protecting groups, Boc and TBS, were cleaved. In fact, 4 M HCl in dioxane was 
cooled to 0 0C using an ice-water bath under an argon atmosphere. Following this, the 
dipeptide was added in one portion at 0 0C and the ice bath was removed, and the mixture 
was stirred for 30 min at room temperature. The reaction was monitored via TLC, and 
upon completion, the mixture was concentrated in vacuo and the residue was washed 
with dry ether. The 1H NMR and 13C NMR (see Appendices 5 and 6) analysis of the 
dipeptide salt indicated the removal of both protecting groups, Boc as well as TBS 
(Scheme 4).  
 
Scheme 4:	  Attempted removal of the Boc group from the dipeptide Boc-Ser(O-TBS)-Ser-
OMe.	  
For this reason, the experimental conditions such as the reaction temperature, and the 
reaction time were altered to see if the result might change. The reaction was run again 
for about 15 min at room temperature. Unfortunately, the same result was obtained since 
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the NMR data.  The selectivity of the Boc removal in the presence of TBS group using 4 
M HCl in dioxane depends on the nature of the dipeptides, and it was not achieved in 
case of the primary alcohol silyl protection. Cavelier and Enjalbal reported the selective 
removal of Boc group was only achieved when the protected alcohol was phenolic.38 For 
that reason, the protecting group (Boc) needed to be changed to another group that is not 
acid labile, so it can be removed selectively without affecting the TBS group. One such 
group could be the Fmoc group.  
2.3 Synthesis of the tetraoxazole macrocyclic peptide with TBS 
groups using a Fmoc protecting group 
2.3.1 Synthesis of Fmoc-Ser-OH(O-TBS) 
Synthesis of the macrocyclic peptide began by first converting the side chain (hydroxyl 
group) of L-serine to a TBS ether. The TBS group was first introduced to the amino acid 
serine Ser-OH with TBSCl and imidazole as a base to give Ser-OH(O-TBS) (4) in 
excellent yield 80% (Scheme 5).40 The structure was confirmed via 1H NMR and 13C 
NMR (see Appendices 7 and 8).  
 
 
Scheme 5:	  Synthesis of Ser-OH(O-TBS).	  
After the protection of the hydroxyl group, the Fmoc group was used to protect the amine 
group in Ser-OH(O-TBS) (4) to afford Fmoc-Ser-OH(O-TBS). The Fmoc group was 
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introduced with 9-fluorenylmethoxycarbonyl chloride (Fmoc-Cl) as a reagent in the 
presence of Na2CO3,41 but unfortunately the reaction did not yield the desired product. 
The Fmoc group was attached to the amine group, but the TBS group was lost. One 
contributing factor could be the formation of HCl, which may have the potential to cleave 
the TBS group.  
Because of the difficulty to protect the amine with the bulky Fmoc group, the protection 
sequence was reversed. The TBS group was introduced to the commercially available 
Fmoc-L-serine. From this introduction, the reaction of Fmoc-L-Ser with TBSCl and 
imidazole in DMF gave the product Fmoc-Ser-OH(O-TBS) (5) in 60% yield along with 
unreacted starting material Fmoc-Ser-OH (Scheme 6).42 The structure was confirmed via 
1H NMR and 13C NMR (see Appendices 9-12).  
 
Scheme 6: Synthesis of Fmoc-Ser-OH(O-TBS) from Fmoc-Ser-OH. 
 
2.3.2 Synthesis of Fmoc-Ser(O-TBS)-Ser-OMe 
After the protection of the serine side chain, a peptide coupling reaction with serine 
methyl ester was used to generate the protected dipeptide. The coupling reagent HBTU 
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was utilized to facilitate the peptide bond formation. The dipeptide Fmoc-Ser(O-TBS)-
Ser-OMe (6) was generated by using the free acid Fmoc-Ser(O-TBS) (5), the 
hydrochloride of H2N-Ser-OMe at 0.1 M concentration, the coupling reagent HBTU and 
DIEA in DCM (Scheme 7).37 The work up was done via an acid-base extraction, 
followed by purification through crystallization with hot hexane to obtain the dipeptide as 
a white solid in 80% yield. As a result of this purification process, the tetramethylurea 
by-product was removed from the dipeptide. The structure of the pure dipeptide, Fmoc-
Ser(O-TBS)-Ser-OMe (6), was confirmed by 1H NMR and 13C NMR (see Appendices 
13-17).  
 
 
Scheme 7:	  Synthesis of the dipeptide Fmoc-Ser(O-TBS)-Ser-OMe. 
	  
2.3.3 Synthesis of heterocyclic oxazole ring  
The heterocyclic ring, oxazole, is formed from the condensation of the serine side chain 
with the preceding carbonyl group in the peptide sequence. The most extensively used 
method for oxazole formation nowadays involves two steps, the first being the formation 
of the intermediate oxazoline. This can be generated by the activation of β-hydroxyl 
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amide from the dipeptide, which is required for cyclization to take place. The activation 
can be achieved by using dehydrating reagents such as methyl N-
(triethylammoniumsulphonyl)carbamate (Burgess reagent)43,44 or diethylaminosulphur 
trifluoride (DAST) reagent in a manner similar to that previously reported.45,46 The 
second step is the oxidation of the intermediate oxazolines to provide the desired 
oxazoles.   
2.3.3.1 Oxazoline formation 
2.3.3.1.1 Reaction using Burgess reagent 
The formation of the intermediate oxazoline was initially attempted by the cyclization of 
the β-hydroxy amide with the Burgess reagent. It is a mild and selective dehydrating 
reagent that was used by Peter Wipf in the formation of 5-membered heterocycles from 
their acyclic precursors.43,44 In order for cyclization to occur, the activation of the 
hydroxyl amide is required. To explain, the synthesis of oxazoline was achieved by 
adding the Burgess reagent to the protected dipeptide (0.1 M) (6) dissolved in anhydrous 
THF (Scheme 8). The reaction mixture was refluxed at 75 0C, and TLC was used to 
monitor the reaction. After a 2 h time period the reaction was complete with all starting 
material having disappeared. The solvents were evaporated under reduced pressure to 
give the crude product that was subsequently purified with column chromatography. The 
pure Fmoc-oxazoline-OMe (7) was obtained as a white solid in a low yield of around 
25%, and the structure was characterized by 1H and 13C NMR (see Appendices 18-22).  
 
Scheme 8:	  Synthesis of Fmoc-oxazoline-OMe using Burgess reagent.	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The low yield of the oxazoline was due to the formation of the opened chain dehydration 
product (Scheme 8) as a by-product as indicated by NMR analysis. In addition, the 
intermediate, oxazoline, was decomposed through the purification by column 
chromatography as well as in organic solution. Decomposition of the oxazoline was 
noticed during the purification as indicated by TLC, and was hence the reason for the low 
yield. It was also observed in other studies done by Miller and co-workers that oxazoline 
is slightly unstable and it decomposed during column chromatography.47 Therefore, dry 
column chromatography was done on the crude mixture and the solvents were evaporated 
in vacuo right away to avoid being in solution to give the oxazoline as a white solid in an 
excellent yield of 70%.  
Furthermore, the Burgess reagent is sensitive to moisture and oxygen and is not even 
stable when it is stored at low temperature.48 With time the quality of the reagent 
decreased, and it become less effective. After further analysis, the yield of the oxazoline 
decreased to 20% when the Burgess reagent was stored in the lab for more than one 
month at low temperature. In order to improve the yield of the oxazoline, the 
concentration of the Burgess reagent was increased to 1.5 and then to 2.0 equivalents, in 
addition to increasing the reaction time. However, the yield of oxazoline was the same 
and could not be improved.    
2.3.3.1.2 Reaction using DAST reagent 
  
Another dehydrating reagent was used in order to improve the yield of the oxazoline 
formation reaction. DAST reagent was used for cyclodehydrative conversion of β-
hydroxy amide to oxazoline at low temperature.45,46 In fact, the β -hydroxy amide (6) was 
treated with DAST reagent in anhydrous DCM at -78 0C for 1 h, followed by the addition 
of anhydrous K2CO3 at the same temperature (Scheme 9).49 
	  	   27	  
 
Scheme 9:	  Synthesis of Fmoc-oxazoline-OMe using DAST reagent. 
 
Then the reaction was allowed to warm to room temperature. Based on the TLC, 
disappearance of the starting material, the formation of oxazoline was observed and 
extraction with NaHCO3 was done. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was subjected to dry column chromatography 
on SiO2 using a hexane and ethyl acetate mixture to achieve the desired oxazoline (7) in 
an excellent yield. The pure oxazoline (7) was obtained as a white solid in 80% yield, and 
its structure was confirmed by 1H NMR and 13C NMR. As a result, the DAST reagent 
offers many advantages over the Burgess reagent, in that it is more stable than the latter 
reagent. Furthermore, the DAST reagent gave a higher yield of the product, oxazoline, 
than the Burgess reagent. 
2.3.3.2 Oxazole formation 
 
In the method established by Williams and co-workers, the oxidation reaction uses 
bromotrichloromethane (BrCCl3) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), 
Scheme 10.50,51 The reaction was achieved to give the oxazole in 80% yield, but the 
presence of base, DBU, caused cleavage of  the Fmoc group. As a result, not only was the 
oxidation of oxazoline (7) to desired oxazole achieved using the DBU/BrCCl3 oxidation 
system, but the Fmoc protecting group was removed, giving H2N-oxazole-OMe (8) as a 
final product. To further explain, the reaction using BrCCl3 and DBU is incompatible 
with the presence of Fmoc protecting group because the Fmoc group can be cleaved with 
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50% DBU in 5 min.52 Therefore, cleaving the Fmoc group during this process was 
beneficial because it saved having to cleave the Fmoc group from the Fmoc-oxazole-
OMe, meaning it is a one-pot deprotection-oxidation reaction and that was confirmed by 
1H NMR (see Appendix 23).  
 
 
Scheme 10:	  Synthesis of H2N-oxazole-OMe.	  
Synthesis of oxazole can also be achieved in a one-pot process using Fmoc-Ser(O-TBS)-
Ser-OMe (6) as a starting material. The synthesis of oxazole by one-pot 
cyclodehydration-dehydrogenation reaction from the dipeptide was obtained using DAST 
reagent and DBU/BrCCl3 (Scheme 11).49,53 
 
Scheme 11:	  One-pot synthesis of H2N-oxazole-OMe from the dipeptide.	  
First, the dehydration reaction with the DAST reagent was initiated at -78 0C for 1 h. 
Followed by dehydrogenation reaction, the addition of DBU was done at -40 0C and 
BrCCl3 at 0 0C, and the reaction was stirred overnight at room temperature. As mentioned 
earlier, the oxidation using DBU/BrCCl3 was achieved smoothly, and Fmoc group was 
also removed, resulting in H2N-oxazole-OMe (8) in % 70 yield. 
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Because the fully protected monooxazole namely Fmoc-oxazole-OMe needed to be 
synthesized, an effort was made to look for alternative methods to form this compound. 
Subsequent treatment of the amine, H2N-oxazole-OMe (8), with Fmoc-OSu in DMF 
afforded the fully protected monooxazole (9) (Scheme 12).54 The reaction was run 
overnight and then subjected to column chromatography to provide the Fmoc-oxazole-
OMe (9); however, this resulted in only 40% yield. The structure was confirmed via 1H, 
and 13C NMR spectra (see Appendices 24-28). Hence, this route had more steps and a 
lower the overall synthesis yield, an effort was made to look for alternative methods to 
oxidize Fmoc-oxazoline-OMe (7) to Fmoc-oxazole-OMe (9) without affecting the Fmoc 
group.  
 
 
Scheme 12: Protect the amine in H2N-oxazole-OMe with Fmoc group.	  
 
 
Preliminary studies were done in order to oxidize the intermediate oxazoline (7) to 
oxazole (9) using a variety of oxidizing agents and conditions, including nickel peroxide 
(NiO2),55,56 N-bromosuccinimide (NBS) with either peroxide57 or K2CO3,58 and 
molecular oxygen with either K2CO359 or Cu(OAc)2.60 However, all to no avail as 
demonstrated by TLC and NMR analysis; in each reaction either the starting material did 
not react or unidentifiable material resulted.  
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The conversion of Fmoc-oxazoline-OMe (7) to Fmoc-oxazole-OMe (9) was also tested 
by employing an excess amount of activated manganese dioxide (MnO2). First, the 
reaction was run in DCM at room temperature overnight using an excess of MnO2 (10 
equivalents), but no cyclization was achieved even when the equivalents of MnO2 were 
increased to 20 equivalents and the temperature to 40 0C.61,62Oxazole formation was 
achieved after changing the solvent to cyclohexane, using 20 equivalents of MnO2, and 
increasing the temperature to 80 0C for 2 days (Scheme 13). The work up involved 
filtering the reaction mixture through celite, washing the celite with EtOAc, and purifying 
the crude product by column chromatography using EtOAc and hexane.  
 
Scheme 13:	  Synthesis of Fmoc-oxazole-OMe, utilizing MnO2.	  
Unfortunately, the oxazoline to oxazole oxidation utilizing MnO2 in refluxing 
cyclohexane produced a disappointing result. The yield of the experiment was found to 
be batch dependent, meaning the yield was different in every reaction even though 
conditions were left largely unchanged. From the given results of each experiment, the 
yield ranged from 20% to 40%. The reason for the low yield may have something to do 
with some of the compound remaining in the celite during the work up because the yield 
of the crude product was low before the column was done.  
 
The best result for the oxidation of the oxazoline (7) to oxazole (9) was obtained using 
the Kharasch-Sosnovsky reaction which involves a cocktail of Cu(I) and Cu(II) salts 
together with  tert-butyl perbenzoate. The oxazoline (7) was oxidized by employing a 
mixture of Cu(OAc)2, CuBr, and tert-butyl perbenzoate in refluxing benzene for 12 h 
(Scheme 14).57 The mixture was cooled to room temperature, diluted with ethyl acetate 
and washed with 10% NH4OH in order to remove the copper salts. This ethyl acetate 
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washing process was repeated three times. The combined organic layers were dried over 
MgSO4 and the solvents were evaporated in vacuo. The crude product was purified by 
column chromatography on SiO2 and using an EtOAc/hexane system to provide the 
Fmoc-oxazole-OMe (9) as a pale yellow solid in 20-43 % yield. In addition, the reaction 
time was increased to 24h to see if that could improve the yield of oxazole, but the yield 
stayed the same.  
 
Scheme 14: Synthesis of Fmoc-oxazole-OMe, utilizing CuBr, Cu(OAc)2. 
 
 
2.3.4 Acid deprotection using NaOH and CaCl2 
Hydrolysis of the methyl ester protecting group from the monooxazole, Fmoc-oxazole-
OMe (9), was achieved by utilizing NaOH and CaCl2 in i-PrOH/H2O (Scheme 15).29 
This was done by dissolving the protected monooxazole in i-PrOH/H2O to a 0.1 M 
concentration with NaOH and CaCl2. The reaction was monitored by TLC, and within 4 h 
the reaction was completed. The crude free acid Fmoc-oxazole-COOH (10) was obtained 
as a white solid in 70 % yield that was used in the next reaction without further 
purification. The structure of free acid was confirmed by 1H NMR (see Appendix 29).  
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Scheme 15:	  Synthesis of Fmoc-oxazole-COOH.	  
 
2.3.5 Synthesis of dioxazole 
Coupling of the free acid Fmoc-oxazole-COOH (10) and free amine H2N-oxazole-OMe 
(8) using the coupling reagent HBTU gave the dioxazole amide (11). During this process 
the free acid (10) was dissolved in DMC to a 0.1 M concentration, and HBTU was added 
at room temperature. After the mixture was cooled to 0 0C, the base, DIEA, was added. 
The free amine (8) was added last, and the reaction was stirred for 1 h at 0 0C and then 
stirred at room temperature for 12h (Scheme 16). The work up was done via an acid-base 
extraction, and the pure dioxazole (11) was obtained, after column chromatography using 
EtOAc and hexane, as a white solid in 50% yield. The structure of pure dioxazole was 
confirmed by 1H NMR and 13C NMR (see Appendices 30-33). 
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Scheme 16: Synthesis of the dioxazole. 
 
When the reaction time was increased from 12 h to 2 days, the yield was decreased to 
35 %. The low yield of the reaction occurred because some of the Fmoc group was 
cleaved. The presence of the base, DIEA, could have slowly cleaved some the Fmoc 
group over the 2 day period.52 
2.3.6 The first route to generate the tetraoxazole using two 
dioxazoles 
The dioxazole (11) was divided into two portions, one portion to cleave the methyl ester 
group, and another to remove the Fmoc group as shown in the Scheme 17.  The 
hydrolysis of the methyl ester group was achieved by utilizing NaOH and CaCl2 in i-
PrOH/H2O. The crude free acid Fmoc-dioxazole-COOH (12), a white solid, was prepared 
in 70% yield and was used in the next coupling reaction without further purification. The 
structure was confirmed via 1H NMR (see Appendix 34). In the second portion of the 
synthesis, the Fmoc group was removed from the dioxazole (11) using the base, DBU, in 
DCM. This process provided the crude free amine (13) in 75% yield that was used in the 
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next step without further purification, and the structure was confirmed via 1H NMR (see 
Appendix 35). 
 
Scheme 17: The first route to generate the tetraoxazole. 
 
Synthesis of the tetraoxazole (14) using a convergent approach involved the coupling of 
the free acid dioxazole (12) and the free amine dioxazole (13). To generate the 
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added to the solution at 0 0C, followed by the free amine H2N-dioxazole-COOH (13) 
(Scheme 17). The reaction mixture was left to stir at room temperature for 12 h. Upon 
completion, confirmed by TLC, the crude tetraoxazole was isolated using an acid-base 
extraction. The pure tetraoxazole (14) was eluted from a SiO2 column using an 
EtOAc/hexane solvent system yielding a white solid in 80% yield. The structure was 
confirmed via 1H NMR and 13C NMR (see Appendices 36-40).  
2.3.7 The second route to generate the tetraoxazole 
2.3.7.1 Synthesis of trioxazole  
Because of the low yield of the oxidation step to form Fmoc-oxazole-OMe (9), which is 
the precursor to form the dioxazole (11), an alternative route to form the tetraoxazole (14) 
was investigated. Instead of using a convergent approach that divides the dioxazole (11) 
into two portions to form the tetraoxazole (14) mentioned above, a stepwise approach 
was developed in order to improve the yield. During the former approach, the methyl 
ester group was hydrolyzed to form the free acid dioxazole (12) and was subsequently 
coupled with the monooxazole, H2N-oxazole-OMe (8), to form trioxazole (15). On other 
worlds, the methyl ester group was cleaved from the dioxazole (11) to form the free acid 
using NaOH and CaCl2 in i-PrOH/H2O. The free acid (12) was obtained as a white solid 
in 92% yield and used in the next coupling reaction without further purification. The free 
acid (12) was coupled with the free amine monooxazole, H2N-oxazole-OMe (8), to form 
the trioxazole (15). The coupling reaction was carried out as previously described, using 
HBTU as a coupling reagent and DIEA as a base in DCM (Scheme 18). The work up was 
achieved by an acid-base extraction, and the crude product was purified by trituration 
with hot hexane to give the trioxazole in 75% yield. The pure trioxazole was 
characterized with 1H NMR and 13C NMR (see Appendices 41-42). 
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Scheme 18:	  Synthesis of trioxazole.	  
 
2.3.7.2 Synthesis of the linear tetraoxazole  
The methyl ester group was cleaved from the trioxazole (15) with NaOH and CaCl2 in i-
PrOH/H2O as mentioned earlier (Scheme 19). The crude free acid, Fmoc-trioxazole-
COOH (16), was obtained as a white solid in 72% yield and used in the next reaction 
without further purification. The structure was characterized with 1H NMR and 13C NMR 
(see Appendix 43). 
The tetraoxazole (14) was synthesized using the free acid, Fmoc-trioxazole-COOH (16), 
the free amine, H2N-oxazole-OMe (8), combined with the coupling reagent HBTU, and 
the base, DIEA, (Scheme 19). The reaction was stirred for 12 h at room temperature, and 
the crude tetraoxazole was isolated using an acid-base extraction followed by purification 
by column chromatography. The pure tetraoxazole (14) eluted with 60:40 EtOAc/hexane, 
was a white solid obtained in 70% yield. The structure and the purity were confirmed by 
1H NMR and 13C NMR. This stepwise approach gave a slightly higher yield than the 
convergent approach. 
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Scheme 19:	  The second route to generate the tetraoxazole.	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2.3.8 Deprotection of tetraoxazole 
Two methods were used to provide the doubly deprotected tetraoxazole (18). The first 
method involved deprotecting the methyl ester group as well as the Fmoc group of the 
tetraoxazole (14) under basic conditions in one step since both of them are base labile.63 
For this method, 0.2 mmol of tetraoxazole dissolved in 1.3 ml of MeOH/THF (1:1 v/v) 
was added to 1.3 ml of 0.15 M NaOH. The mixture stirred at room temperature overnight, 
and the organic solvents were evaporated. The residue was diluted with water and 
acidified with 0.5 N NaHSO4. The mixture was then extracted with DCM, dried over 
MgSO4, filtered, and concentrated. The solid that was obtained was analyzed by NMR 
and was not the desired product. It is plausible that the desired compound remained in the 
aqueous phase due to its polar nature when the work up was completed.  
The second method that was used to give the deprotected tetraoxazole (18) involved a 
step-wise approach. In this method, standard acid and amine deprotection conditions 
were applied respectively (Scheme 20). 
 
Scheme 20: Synthesis of the deprotection tetraoxazole. 
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First, the methyl ester group was cleaved using NaOH and CaCl2 in i-PrOH/H2O to 
generate free acid Fmoc-tetraoxazole-COOH (17). The free acid was obtained after 24 h 
of reaction time in 75% yield, and was taken on to the next deprotection step without 
further purification. Next, the Fmoc group was removed utilizing DBU in DCM to 
provide the doubly deprotected tetraoxazole (18). The crude doubly deprotected 
tetraoxazole was analyzed via 1H NMR (see Appendix 44), and an impurity, 
dibenzofulvene, was generated from Fmoc cleavage. Therefore, the first method did not 
give the desired product, and the second method worked in 75% yield. 
2.3.9 Macrocyclization to generate tetraoxazole macrocyclic 
peptide  
Cyclization reactions are totally different from coupling reactions that provide di-, tri-, 
and tetraoxazole because the cyclization reactions are run under very dilute conditions 
(<0.01 M). To explain, cyclization reactions run at a concentration of 0.001 M, whereas 
the coupling reactions that were previously described occurred at 0.1 M. The 
concentration of the cyclization reactions is critical in order to prevent intermolecular 
side reaction since macrocyclization relies on intramolecular ring closure. These dilute 
conditions help the peptide to generate a macrocyclic peptide, so it provides 
intramolecular reaction.27 
Thus, the doubly deprotected linear precursor H2N-tetraoxazole-COOH (18) was allowed 
to react under a very diluted concentration using coupling reagent O-[(1-cyano-2-ethoxy-
2-oxoethylidene)amino]-oxytri(pyrrolidin-1-yl) phosphonium hexafluoro-phosphate 
(PyOxim) and base, DIEA, in DMF. The most potent phosphonium salt nowadays is 
PyOxim that has an excellent solubility in most organic solvents like DMF. This salt 
gives high coupling efficiency not only in peptide coupling but also in cyclic peptide 
synthesis.64 In contrast to HBTU, PyOxim is stable in solution under inert atmosphere for 
2 days. Moreover, since HBTU is such a reactive coupling reagent that leads to side 
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reactions, usually during a slow coupling reaction like cyclization, PyOxim is a perfect 
coupling reagent for the synthesis of cyclic peptides.64 
In order to generate the tetraoxazole macrocyclic peptide (19), the coupling reagent 
PyOxim, and DIEA were combined with the deprotected tetraoxazole (Scheme 21). The 
coupling reagent and the base were dissolved in dry DMF to a 0.001 M concentration, 
and a solution of the deprotected tetraoxazole in DMF was added slowly dropwise to the 
mixture. The reaction mixture was stirred for 3 days, and the crude macrocyclic peptide 
was subjected to an acid-base extraction. The crude product was purified by column 
chromatography using an EtOAc/hexane solvent system to give the macrocyclic peptide 
in 20% yield that was analyzed by 1H NMR (see Appendix 45). Unfortunately, one or 
more (uncharacterized) contaminants were clearly visible in the NMR spectrum. 
Attempts to purify the macrocycle by crystallization in hot hexane were not successful. 
Hence, a pure macrocyclic compound was not obtained. 
 
Scheme 21: Synthesis of the tetraoxazole macrocyclic peptide with TBS groups. 
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2.4 Synthesis of the tetraoxazole macrocyclic peptide with t-Bu 
groups 
In summary, the major difficulty in providing the macrocyclic peptide was the low yield 
of the oxidation reaction, forming the intermediate Fmoc-oxazole-OMe (9), and 
compounds produced from it. To explain, the Fmoc group was sensitive to the 
experimental conditions used in the oxidation reaction and was easily removed. To 
improve the yield of the oxidation step, the starting material amino acid as well as the 
protecting groups in the amino acid were changed. Boc-Cys(t-Bu)-OH was used instead 
of Fmoc-Ser-OH(OTBS). Once this change was made, an improvement of the oxidation 
step was noticed. The yield for the oxidation step to get the fully protected monooxazole 
(Boc-oxazole-OMe) was 48% in three steps whereas the yield for Fmoc-oxazole-OMe 
was 20% in four steps. 
2.4.1 Synthesis of the dipeptide Boc-Cys(t-Bu)-Ser-OMe  
Synthesis of the second macrocyclic peptide began with the condensation of amino acids 
Boc-L-Cys(t-Bu)-OH and HCl.H2N-L-Ser-OMe using HBTU as coupling reagent. The 
free acid Boc-L-Cys(t-Bu)-OH, and the HBTU were added into a flask and dissolved in 
DCM to a 0.1 M concentration (Scheme 22). Following this, the base, DIEA, and the free 
amine as a salt Ser-OMe.HCl were added to the reaction mixture at 0 0C. The crude 
dipeptide was purified by crystallization with hot hexane to provide the pure dipeptide 
Boc-Cys(t-Bu)-Ser-OMe (20) as a white solid in 100% yield. The pure dipeptide was 
confirmed by using 1H NMR and 13C NMR (see Appendices 46 and 47).  
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Scheme 22: Synthesis of the dipeptide Boc-Cys(t-Bu)-Ser-OMe.  
	  
 
2.4.2 Synthesis of the oxazole ring (Boc-oxazole-OMe) 
Cyclodehydration of the β-hydroxy amide was performed by fluorination with the DAST 
reagent. The dipeptide (20) was dissolved in dry DCM to 0.1 M concentration at -78 0C 
and under nitrogen gas. DAST reagent was added dropwise over 15 min to the reaction 
flask and stirred for 2 h. K2CO3 was added to the reaction and stirred for 1 h at the same 
temperature (Scheme 23). The reaction was monitored with TLC, and upon completion 
the crude reaction mixture was diluted with DCM, washed with NaHCO3, dried over 
MgSO4, filtered, and concentrated. The oxazoline intermediate was used in the next step 
without further purification.  
The oxazoline intermediate was directly subjected to an oxidation reaction using 
DBU/BrCCl3 (Scheme 23). The oxazoline was dissolved in anhydrous DCM at a 0.1 M 
concentration, and the base, DBU, was added dropwise at 0 0C under argon gas. After the 
reaction had been stirred for 5 min, BrCCl3 was added dropwise to the flask. The crude 
oxazole was purified by column chromatography using an EtOAc/hexane solvent system. 
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The 3 step process yielded 48% pure Boc-oxazole-OMe (21) and its structure was 
confirmed by using 1H NMR and 13C NMR (see Appendices 48 and 49).  
 
Scheme 23:	  Synthesis of Boc-oxazole-OMe.	  
 
 
2.4.3 Hydrolysis of the methyl ester group using LiOH  
The protected monooxazole, Boc-oxazole-OMe (21), was split into two portions: one to 
cleave the methyl ester group and another to remove the Boc group. Deprotection of Boc-
oxazole-OMe (21) to generate the acid Boc-oxazole-COOH (22) was carried out under 
basic conditions. More specifically, the monooxazole was dissolved in THF, to a 0.1 M 
concentration, and then a solution of LiOH in H2O was added dropwise to the reaction 
mixture at 0 0C (Scheme 24).21 The reaction mixture was stirred and monitored by TLC, 
up until completion. The free acid Boc-oxazole-COOH (22) was obtained as a yellow 
solid in 45% yield, and the structure was analyzed with 1H NMR and 13C NMR (see 
Appendices 50 and 51).  
 
Scheme 24:	  Synthesis of Boc-oxazole-COOH.	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2.4.4 Boc group removal  
With Boc-oxazole-OMe (21) in hand, cleaving the Boc group was achieved under acidic 
condition by using 4 M HCl/1,4 dioxane (Scheme 25).39 This process consisted of 
dissolving the Boc-oxazole-OMe (21) in anhydrous THF at 0.3 M concentration followed 
by the addition of 4 M HCl/1,4 dioxane at 0 0C and under nitrogen gas. Monitored by 
TLC up until the disappearance of starting material, the reaction was completed in 2 h at 
room temperature. The solvents were evaporated in vacuo, and the residue was washed 
with dry ether. Simple decantation was used to provide the HCl salt of amine 
monooxazole, HCl.H2N-oxazole-OMe (23), in a quantitative yield. The structure was 
analyzed with 1H NMR and 13C NMR (see Appendices 52 and 53). 
Scheme 25: Synthesis of HCl.H2N-oxazole-OMe. 
 
2.4.5 Synthesis of dioxazole 
Coupling of free acid, Boc-oxazole-OMe (22), with free amine monooxazole, HCl.H2N-
oxazole-OMe (23), provided the dioxazole amide (24) under the coupling reaction 
condition described above. The free acid (22) and the coupling reagent HBTU were 
dissolved in DCM for an overall concentration of 0.1 M. Following this, the base, DIEA, 
was added slowly at 0 0C under nitrogen gas, and the free amine (23) was added last 
(Scheme 26). The reaction was stirred overnight at room temperature. An acid-base 
extraction was used to isolate the crude dioxazole. Column chromatography was used to 
obtain the pure dioxazole (24) in 80% yield, and the structure was confirmed by using 1H 
NMR and 13C NMR (see Appendices 55 and 56). 
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Scheme 26:	  Synthesis of dioxazole Boc-dioxazole-OMe. 
	  
 
2.4.6 Synthesis of trioxazole (Boc-trioxazole-OMe) 
Due to the small quantity of the dioxazole amide (24), instead of dividing the dioxazole 
amide into two fractions, the methyl ester was cleaved from the dioxazole amide (24) to 
get the acid (25) that could be coupled with the amine monooxazole (23). The methyl 
ester group was removed with LiOH in H2O/THF, providing the dioxazole-COOH (25) 
as a white solid in 75% yield. The structure was analyzed with 1H NMR and 13C NMR 
(see Appendices 56 and 57). Following this step, the trioxazole was achieved by utilizing 
the coupling reagent N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC) with 1-hydroxybenzotriazole (HOBt).65 EDC is a carbodiimide reagent that is 
used to activate a carboxylic acid, and it is such a reactive reagent that can cause 
racemization of the amino acids and produce side reactions during the coupling.  Thus, 
the addition of an additive such as HOBt can minimize racemization and avoid the 
formation of unreactive side-reactions. Moreover, EDC is highly suitable for use in 
solution phase peptide synthesis because EDC and its urea by-product are soluble in 
water and can be removed by aqueous workup.66   
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The free amine HCl.H2N-oxazole-OMe (23) was added to a cold solution of free acid 
Boc-dioxazole-COOH (25) in DCM to a concentration of 0.1 M. Followed by the 
addition of EDC.HCl and HOBt; the reaction was stirred for 5 min before the base, DIEA, 
was slowly added (Scheme 27). The reaction stirred overnight, and then the crude 
reaction mixture was subjected to acid-base extraction and further purification by 
crystallization with hot hexane. The pure protected trioxazole, Boc-trioxazole-OMe (26), 
was furnished as a solid in 85% yield and the structure was confirmed via 1H NMR and 
13C NMR (see Appendices 58 and 59). 
 
Scheme 27:	  Synthesis of Boc-trioxazole-OMe.	  
 
2.4.7 Synthesis of tetraoxazole (Boc-tetraoxazole-OMe)  
Having attained the fully protected trioxazole, the methyl ester protecting group of Boc-
trioxazoles-OMe (26) was removed in order to prepare the acid (27) so that it could be 
coupled with amine monooxazole (23) to obtain the tetraoxazole (Scheme 28). Boc-
trioxazole-OMe (26) was dissolved in THF to a 0.1 M concentration, and LiOH in H2O 
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completion, a process lasting 3 h. The reaction mixture was acidified with 1N NaHSO4 
and extracted with EtOAc. The organic layer was dried over MgSO4, filtered, and 
concentrated to provide the free acid in 91% yield. The structure of the pure acid, Boc-
trioxazole-COOH (27), was confirmed by using 1H NMR (see Appendix 60).  
Boc-tetraoxazole-OMe (28) was synthesized by coupling the acid, Boc-trioxazole-COOH 
(27), with the free amine, HCl.H2N-oxazole-OMe (23), utilizing EDC.HCl, HOBt, and 
the base, DIEA, in DCM (0.1 M) at 0 0C under argon (Scheme 28). The reaction mixture 
stirred for 1 h at the same temperature then at room temperature overnight. The reaction 
mixture was then subjected to acid-base extraction, followed by purification via column 
chromatography. The crude product was first eluted with a DCM/MeOH solvent system 
from a SiO2 column to provide the pure compound, however, no separation was obtained. 
This may have been due to the solubility of the crude product in the DCM/MeOH solvent 
system being too high. Therefore, the purification of the crude product was repeated, but 
this time with an EtOAc/hexane solvent system on SiO2. The pure Boc-tetraoxazole-OMe 
(28) was obtained as a white solid in 30% yield. The structure was confirmed by using 1H 
NMR and 13C NMR (see Appendices 61 and 62).   
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Scheme 28:	  Synthesis of the tetraoxazole.	  
 
2.4.8 Synthesis of the fully deprotected tetraoxazole (HCl.H2N-
tetraoxazole-COOH) 
 
The formation of unprotected tetraoxazole involved a stepwise approach by utilizing acid 
and then amine deprotection conditions (Scheme). First, the methyl ester group was 
removed using LiOH in H2O/THF to provide the free acid (29) in 90% yield that was 
used in the next deprotection step without further purification. Second, 4 M HCl/1,4 
dioxane was used to remove the Boc group in anhydrous THF. After dissolving the Boc-
tetraoxazole-COOH (29) in THF, 4 M HCl/1,4 dioxane was added to the mixture at 0 0C 
under a nitrogen atmosphere. The reaction mixture was stirred for 4 h at room 
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temperature and then THF was evaporated in vacuo. The residue was washed with dry 
ether and collected by filtration. An analysis of the sample by NMR, revealed the Boc 
group to be still attached to the amine group. As a result, the deprotection of the Boc 
group was repeated using the same method except that the reaction was run for 8 h. The 
work up was done in the same manner as before and the resulting compound (30) was 
analyzed by the 1H NMR (see Appendix 63). Unfortunately, the Boc group and the t-Bu 
group were removed using the longer reaction time. The final step to form the 
macrocyclization is not expected to work because of the unprotected side chain of the 
tetraoxazole. 
 
Scheme 29: Synthesis of deprotected tetraoxazole. 
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2.4.9 Macrocyclization of the tetraoxazole macrocyclic peptide  
The macrocyclization reaction was tested using the same condition used in preparing the 
first macrocyclic peptide (19). The reaction was run with PyOxim as a coupling reagent 
and DIEA as a base under dilute conditions (0.001 M). The reaction was stirred for 3 
days, and the crude mixture was subjected to an acid-base extraction. The crude was 
purified by column chromatography on SiO2 using an EtOAc/hexane solvent system. 
Even though the starting material reacted, according to the TLC results, the anticipated 
cyclic product was not obtained. Although the reason for the absence of the macrocycle 
in the reaction mixture is not known, it is possible that partial oxidation of the free 
sulfhydryl groups (leading to the formation of disulfides) could lead to a higher rigidity 
of the tetraoxazole, hence impairing the attack of the free N-terminal amine on the 
activated C-terminal carboxylate. Alternatively, it might be possible that some of the free 
thiol groups of the tetraoxazole reacted with the PyOxim-activated C-terminal 
carboxylate to form a thioester (instead of the N-terminal amine group).  
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Chapter 3- Experimental Methods 
3.1 General remarks about reagents and instruments  
All reactions were carried out under a nitrogen atmosphere with dry organic solvents, 
unless otherwise noted. Some of the organic solvents were dried before use such as 
tetrahydrofuran (THF) and dichloromethane (DCM). THF was distilled over sodium and 
benzophenone whereas DCM was distilled over calcium chloride.  Other organic solvents 
such as anhydrous dimethylformamide (DMF) were used as they were obtained from 
commercially available sources (Fisher, and Sigma-Aldrich). Reagents were obtained 
from commercial sources and were used in the reactions as received without further 
purification.   
All reactions were monitored via thin-layer chromatography (TLC) using TLC plates 
made of silica gel F-254. A mixture of solvents was also used, primarily ethyl 
acetate/hexanes or methanol/DCM. The plates were visualized with ultraviolet light at a 
wavelength of λ = 254 nm and then developed with a ninhydrin solution that was 
prepared by dissolving 5 g of phosphomolybdic acid hydrate in 95 ml of ethanol.  
Column chromatography was performed on two kinds of silica gel (silica gel 60 (70-230 
mesh ASTM) and (230–400 mesh ASTM)) that were obtained from Silicycle (Quebec, 
Canada) and used as the stationary phase. 
All evaporations were carried out at 40 0C under reduced pressure using a rotary 
evaporator. Melting points were determined with a Melting Point Apparatus in capillary 
tubes from Kimble Chase.  
All compounds were analyzed using a Bruker 500 MHz nuclear magnetic resonance 
(NMR) spectrometer at room temperature. Proton (1H) NMR and carbon (13C) were 
recorded in deuterated solvents, and residual undeuterated solvent was used as an internal 
reference. The chemical shifts are quoted in parts per million (ppm), and all coupling 
constants are quoted in Hertz. The following abbreviations were used to explain 
multiplicity of each signal: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = 
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multiplet, brd = broad, bd = broad doublet, dd = doublet of doublet, and dq = doublet of 
quartet. 13C NMR was further analyzed by distortionless enhancement by polarization 
transfer (DEPT) 135 and DEPT 90 in order to identify carbon peaks. DEPT spectra 
determine the number of hydrogens attached to each carbon in a compound. A DEPT 135 
experiment yields CH and CH3 as positive peaks whereas CH2 as negative signals. In 
addition, a DEPT 90 experiment gives only CH peaks and quaternary carbon peaks are 
disappeared in both DEPT 135 and DEPT 90. Where required, a compound can also be 
analyzed by two-dimensional NMR such as correlation spectroscopy (COSY) of 1H-1H 
correlations which identify coupled protons.  
 
3.2 General experimental procedures 
3.2.1 Solution phase peptide coupling 
Peptide coupling reactions were preformed using different coupling reagents such as 
HBTU or EDC.HCl with HOBt in solution phase synthesis. The reactions were carried 
out under a nitrogen atmosphere with anhydrous DCM. The free acid (1.0 equivalent) 
was weighed in a dry flask then dissolved in dry DCM to give a 0.1 M solution. The 
coupling reagent (1.2 equivalents of HBTU or 1.2 equivalents of EDC.HCl with 1.2 
equivalents of HOBt) was added to the reaction and stirred for 5 min at room 
temperature. After that, the reaction mixture was cooled to 0 0C and the base DIEA (2.5 
equivalents) was added to the reaction flask. Finally, (1.0 equivalent) of the free amine 
was added to the reaction mixture at the same temperature. The reaction was stirred 
overnight while it was allowed to warm up to room temperature. The completion of the 
reaction was assumed by checking the TLC. The reaction was then worked up with an 
acidic aqueous solution like 0.5 N NaHSO4 in order to remove any excess of free amine, 
followed by a wash with saturated NaHCO3 in order to remove the excess of coupling 
agent(s) and their by-products. The organic layers were collected, washed with H2O and 
brine and dried over MgSO4. The filtrate was concentrated in vacuo to give the crude and 
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then column chromatography was performed using an EtOAc/hexane system to give the 
desired purified peptide. 
3.2.2. The deprotection of the Fmoc group 
DBU (2.0 equivalents) was added slowly to a solution of the Fmoc protected peptide in 
DCM (0.1 M) at 0 0C under argon. The resulting mixture was stirred for 1 h at 0 0C, and 
then warmed to room temperature and stirred overnight to ensure complete removal of 
the Fmoc protecting group. The mixture was diluted with DCM and washed with H2O, 
dried over MgSO4 and filtered. The filtrate was concentrated in vacuo to give the free 
amine. 
3.2.3 The deprotection of the Boc protecting group 
The Boc protected compound was dissolved in dry THF (0.1 M) and the solution was 
cooled to 0 0C under N2 gas. 4 M HCl/1,4 dioxane (33.0 equivalents) were added at the 
same temperature and stirred for 5 minutes. The ice bath was then removed and stirring 
continued at room temperature until the reaction was complete as monitored by TLC. The 
mixture was concentrated in vacuo to obtain the free amine as HCl salt. The salt was then 
washed with dry ether several times in order to remove any remaining solvents and HCl.  
3.2.4 The hydrolysis of the methyl ester group 
Two different procedures were used to remove the methyl ester group from the protected 
peptide: the first using NaOH and CaCl2 and the second using LiOH. 
3.2.4.1 Cleaving the methyl ester group using NaOH and CaCl2 
The methyl ester protected peptide was dissolved in H2O: i-PrOH (3:7, 0.1M), and NaOH 
(1.2 equivalents) and CaCl2 (2.5 equivalents) were added to the mixture. The reaction 
was stirred until the TLC showed the disappearance of all starting material. The resulting 
mixture was acidified with 0.5 N NaHSO4. The aqueous layer was extracted twice with 
EtOAc, and the organic layer was washed with water and brine, dried over MgSO4 and 
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filtered. The filtrate was evaporated to give the crude acid that was used in the next 
reaction without further purification. 
3.2.4.2 Cleaving the methyl ester group using LiOH 
The protected compound was dissolved in THF for a 0.1 M concentration and the 
solution was cooled to 0 0C under a nitrogen atmosphere. LiOH.H2O (2.0 equivalents) in 
H2O (0.1 M) was added dropwise over 15 min at 0 0C, and the mixture was then stirred 
and warmed up to room temperature. The progress of the reaction was monitored with 
TLC up until its completion. At that point, the mixture was evaporated in vacuo. The 
residue was diluted with water, acidified with HCl to pH=3 and extracted twice with 
EtOAc. The combined organic layer was washed with brine, dried over MgSO4, filtered 
and concentrated in vacuo to yield the free acid.  
3.2.5 Macrocyclization   
Macrocyclization was performed under diluted condition (0.001 M) using PyOxim (1.2 
equivalents) and base DIEA (3.2 equivalents) in anhydrous DMF at room temperature 
under a nitrogen atmosphere and stirred for 3 days. The solvent was evaporated in vacuo, 
and the residue was then dissolved with DCM. The mixture was washed once each with 1 
N NaHSO4, saturated NaHCO3, water, and brine. The organic layer was dried over 
MgSO4, filtered, and evaporated in vacuo to give the crude macrocyclic peptide that was 
purified by column chromatography on SiO2. 
3.3 Experimental methods for the synthesis of the tetraoxazole 
macrocyclic peptide with TBS groups 
3.3.1 Boc chemistry 
3.3.1.1 Synthesis of Boc-Ser-OH(O-TBS)  (1) 
Boc-L-Ser-OH (1.73 g, 8.43 mmol) was dissolved in DMF (0.2 M, 42.15 ml) and the 
mixture was cooled to 0 0C under a nitrogen atmosphere. TBSCl (1.9 g, 12 mmol) and 
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imidazole (1.77 g, 26.9 mmol) were added to the mixture, which was then stirred for 1 h 
at the same temperature. Following this step, the mixture was warmed to room 
temperature and stirred overnight. The mixture was partitioned between Et2O and H2O 
and the aqueous layer was re-extracted twice with ether. The organic layers were 
combined and dried over MgSO4 and filtered. The filtrate was concentrated in vacuo to 
provide an oily residue that was purified by column chromatography on SiO2 using an 
ethyl acetate, hexane, and AcOH system to afford a 50% yield of Boc-Ser-OH(O-TBS) 
(1) as colorless oil (see Appendices 1 and 2). 1H NMR (500 MHz, Chloroform-d) δ 5.36 
(d, J = 8.3 Hz, 1H; NH), 4.40 (brd, 1H; CH), 4.12 (m, 1H; CH2), 3.85 (dd, J = 10.1, 4.0 
Hz, 1H; CH2), 1.48 (s, 9H; (CH3)3 Boc), 0.90 (s, 9H; (CH3)3CSi(CH3)2), 0.08 (d, J = 5.3 
Hz, 6H; (CH3)3CSi(CH3)2). 13C NMR (126 MHz, CDCl3) δ 175.09; (CO)OH, 155.64; 
(CO)O Boc, 80.29; C(CH3) Boc, 63.41; CH2OSi, 55.21; CHCH2OSi, 28.31; (CH3)3 Boc, 
25.74; (CH3)3CSi(CH3)2, 18.22; (CH3)3CSi(CH3)2, -5.54 (two peaks); (CH3)3CSi(CH3)2. 
3.3.1.2 Synthesis of Boc-Ser(O-TBS)-Ser-OMe (2) 
HBTU (1.5 g, 4.1 mmol) was added to a solution of Boc-Ser-OH(O-TBS) (1) (1 g, 3.13 
mmol) in dry DCM (0.1 M, 30 ml), and then cooled in an ice-water bath to 0 0C under a 
nitrogen atmosphere. DIEA (1.72 ml, 9.92 mmol) was then added, and the reaction 
mixture was stirred for 10 min. HCl.H2N-L-Ser-OMe (0.48 g, 3.13 mmol) was added and 
the reaction mixture was stirred for 1 h at 0 0C.  Following this, the ice-bath was removed 
and the reaction mixture was left to stir overnight at room temperature. The mixture was 
then diluted with DCM and washed once with each 0.5 N NaHSO4, NaHCO3, brine and 
water. The organic layer was dried over MgSO4, filtered and evaporated using vacuo to 
provide the crude dipeptide which was then purified by crystallization with hot hexane to 
provide the dipeptide (2) as a yellow solid in 60% yield (see Appendices 3 and 4), mp 56-
58 0C. 1H NMR (500 MHz, Chloroform-d) δ 7.37 (d, J = 7.1 Hz, 1H; NHCO), 5.39 (brd, 
1H; NH Boc), 4.67 (brd, 1H; CHCH2OSi), 4.20 (b, 1H; CHCH2OH), 4.05 (dd, J = 9.9, 
4.0 Hz, 1H; CH2OSi), 3.96 (brd, 2H; CH2OH), 3.80 (s, 3H; OCH3), 3.74 (dd, J = 9.9, 6.1 
Hz, 1H; CH2OSi), 1.48 (s, 9H; (CH3)3 Boc), 0.91 (s, 9H; (CH3)3CSi(CH3)2), 0.10 (s, 6H; 
(CH3)3CSi(CH3)2). 13C NMR (126 MHz, CDCl3) δ 171.00; (CO)OCH3, 171.47; (CO)NH,  
155.61; (CO)O Boc, 80.42; C(CH3) Boc, 63.27; CH2OSi, 63.18; CH2OH, 55.96; 
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CHCH2OSi, 55.09; CHCH2OH, 52.77; OCH3, 28.29; (CH3)3 Boc, 25.28; 
(CH3)3CSi(CH3)2, 18.23; (CH3)3CSi(CH3)2, -5.54; (CH3)3CSi(CH3)2. 
3.3.1.3 Cleaving the Boc group with 4 M HCl in dioxane H2N-
Ser-OH-Ser-OMe (3) 
4 M of HCl in dioxane (4 ml, 16 mmol) was cooled to 0 0C in round bottomed flask using 
an ice-bath under a nitrogen atmosphere. The dimer Boc-Ser-OH(O-TBS)-Ser-OMe (2) 
(0.084 g, 0.2 mmol) was added into the flask in one portion and the ice-bath was 
removed. The reaction was stirred at room temperature for half an hour, up until the 
disappearance of the starting material monitored by TLC. The solvent was removed 
under reduced pressure, and the residue was then washed with dry ether several times. 
Finally, the solvent was evaporated to give the dimer as H2N-Ser-OH-Ser-OMe (3) in 
70% yield (see Appendices 5 and 6). 1H NMR (500 MHz, Deuterium Oxide) δ 4.57 (t, J 
= 4.2 Hz, 1H; CHCH2OH), 4.13 – 4.09 (t, J = 5.1 Hz, 1H; CHCH2OH), 3.95 (dd, J = 
12.4, 4.0 Hz, 1H; CH2OH), 3.88 (dd, J = 10.8, 5.2 Hz, 2H; CH2OH), 3.80 (dd, J = 11.8, 
3.8 Hz, 1H; CH2OH), 3.68 (s, 3H; OCH3), 3.64 (s, 3H). 13C NMR (126 MHz, Deuterium 
Oxide) δ 171.65; (CO)OCH3, 167.87; (CO)NH, 61.89; CH2OH, 60.14; CH2OH, 54.99; 
CHCH2OH, 54.53; CHCH2OH, 53.13; OCH3. 
 
3.3.2 Fmoc chemistry 
3.3.2.1 Synthesis of Ser-OH(O-TBS) (4) 
Imidazole (1.37 g, 20 mmol) and TBSCl (1.65 g, 11 mmol) were added to a solution of 
L-Ser-OH (1.06 g, 10 mmol) in DMF (0.1M, 100 ml) and stirred overnight. The solvents 
were evaporated under reduced pressure to provide an oily residue and finally, the crude 
was purified by crystallization using hexane and water (1:1) to afford Ser-OH(O-TBS) 
(4) as a white solid in 80% yield (see Appendices 7 and 8). 1H NMR (500 MHz, 
Methanol-d4) δ 4.10 – 4.00 (m, 2H; CH2), 3.66 (dd, J = 5.9, 3.7 Hz, 1H; CH), 0.95 (s, 9H; 
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(CH3)3CSi(CH3)2), 0.14 (d, J = 2.4 Hz, 6H; (CH3)3CSi(CH3)2). 13C NMR (126 MHz, 
CDCl3) δ 168.76; (CO)OH, 60.57; CHCH2OSi, 58.85; CHCH2OSi, 23.40; 
(CH3)3CSi(CH3)2, 16.32; (CH3)3CSi(CH3)2, -8.33; (CH3)3CSi(CH3)2. 
 
3.3.2.2 Synthesis of Fmoc-Ser-OH(O-TBS) (5) 
Imidazole (1.09g, 16mmol) was added to a solution of Fmoc-L-Serine (1.05 g, 3.2 mmol) 
in DMF (6.4 ml) at room temperature. The solution was cooled to 0 0C and TBSCl (1.21 
g, 8 mmol) was added and stirred for 3 h. Following this step, the reaction mixture was 
warmed to room temperature and stirred overnight. The solution was diluted with EtOAc 
to 200ml and washed with NH4Cl (3×40 ml) and H2O (40 ml), then dried over MgSO4 
and concentrated in vacuo to provide a residue. Purification was then performed by using 
column chromatography on silica gel 40-63µm, eluting with 5% methanol, 94% 
dichloromethane and 1% AcOH to provide Fmoc-Ser-OH(O-TBS) (5) as a white solid in 
60% yield (see Appendices 9-12), mp 105-106 0C. 1H NMR (500 MHz, Chloroform-d) δ 
7.80 (d, J = 7.2 Hz, 2H; 2x Fmoc H Ar), 7.64 (t, J = 8.1 Hz, 2H; 2x Fmoc H Ar), 7.43 (t, 
J = 7.3 Hz, 2H; 2x Fmoc H Ar), 7.34 (t, J = 7.2 Hz, 2H; 2x Fmoc H Ar), 5.65 (d, J = 7.2 
Hz, 1H; NH), 4.50 (brd, 1H; αCH), 4.47 – 4.37 (m, 2H; Fmoc CH2), 4.28 (t, J = 7.5 Hz, 
1H; Fmoc CH), 4.18 (dd, J = 9.7, 2.3 Hz, 1H; β CH2), 3.90 (dd, J = 9.6, 4.2 Hz, 1H; 
β’CH2), 0.93 (s, 9H; (CH3)3CSi(CH3)2), 0.11 (d, J = 4.6 Hz, 6H; (CH3)3CSi(CH3)2). 13C 
NMR (126 MHz, CDCl3) δ 174.70; (CO)OH, 156.03; OCONH, [143.67, 141.31, 127.75, 
127.08, 125.10, 120.01]; CH Fmoc Ar, 67.34; CHCH2OSi, 63.25; Fmoc CH2, 55.43; 
CHCH2OSi, 47.10; Fmoc CH, 25.74; (CH3)3CSi(CH3)2, 18.22; (CH3)3CSi(CH3)2, -5.53; 
(CH3)3CSi(CH3)2. 
3.3.2.3 Synthesis of Fmoc-Ser(O-TBS)-Ser-OMe (6) 
HBTU (9.15 g, 24.12 mmol) was used to treat a solution of Fmoc-Ser-OH(O-TBS) (5) 
(8.4 g, 20.16 mmol) in DCM (200 ml, 0.1 M) at room temperature. The flask was then 
placed under a nitrogen atmosphere and the mixture was cooled to 0 0C. Following this 
step, DIEA (11.20 ml, 64.32 mmol) was added to the mixture and stirred for 5 min.  H-
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Ser-L-OMe.HCl (3.14 g, 20.1 mmol) was then added and the resulting mixture was 
stirred at room temperature overnight. Upon the completion of the reaction, the solvent 
was evaporated in vacuo. The resulting residue was diluted with ethyl acetate, washed 
with 0.5 N NaHSO4 and the aqueous layer was re-extracted with ethyl acetate. Next, the 
organic layers were collected and washed with NaHCO3, followed by H2O and brine. The 
organic layer was then dried over anhydrous magnesium sulfate, filtered and concentrated 
in vacuo. Finally, the crude dipeptide was purified by crystallization with an ethyl acetate 
and hexane system to provide the dipeptide (6) (1.7 g, 3.25 mmol) as a white solid in 
80% yield (see Appendices 13-17), mp 125-126 0C. 1H NMR (500 MHz, Chloroform-d) 
δ 7.79 (d, J = 7.5 Hz, 2H; 2x Fmoc H Ar), 7.62 (t, J = 6.0 Hz, 2H; 2x Fmoc H Ar), 7.46 
(brd, 1H; NH amide), 7.43 (t, J = 7.5 Hz, 2H; 2x Fmoc H Ar), 7.34 (t, J = 7.4 Hz, 2H; 2x 
Fmoc H Ar), 5.73 (brd, 1H; NH Fmoc), 4.69 (m, 1H; NHCHCH2OH), 4.43 (d, J = 6.7 
Hz, 2H; Fmoc CH2), 4.30 (brd, 1H; NHCHCH2OSi), 4.26 (t, J = 6.7 Hz, 1H; Fmoc CH), 
4.08 (dd, J = 9.8, 4.1 Hz, 1H; NHCHCH2OSi), 4.04 – 3.94 (m, 2H; CHCH2OH), 3.81 (s, 
3H; OCH3), 3.74 (dd, J = 9.8, 7.1 Hz, 1H; NHCHCH2OSi), 0.94 (s, 9H; 
(CH3)3CSi(CH3)2), 0.13 (s, 6H; (CH3)3CSi(CH3)2). 13C NMR (126 MHz, CDCl3) δ 
170.63; (CO)OCH3, 170.40; CONH amide, 156.15; OCONH, [143.63, 141.31]; C Fmoc 
Ar, 127.75, 127.08, 125.11, 120.01]; CH Fmoc Ar, 67.33; Fmoc CH2, 63.18; CHCH2OSi, 
CHCH2OH, 55.99; CHCH2OSi, 55.01; CHCH2OH, 52.77; OCH3, 47.10; Fmoc CH, 
25.80; (CH3)3CSi(CH3)2, 18.23; (CH3)3CSi(CH3)2, -5.54; (CH3)3CSi(CH3)2.   
 
3.3.2.4 Synthesis of Fmoc-oxazoline-OMe (7) 
3.3.2.4.1 Using Burgess reagent 
A solution of dipeptide (6) (7.16 g, 13.2 mmol) in 131 ml of dry THF (0.1 M) was treated 
with Burgess reagent (3.46 g, 14.5 mmol) and heated to reflux at 75 0C for 2 h. The 
solvent was evaporated to provide an oily residue that was purified using dry column 
chromatography in EtOAc/hexane system to yield oxazoline (7) 25-70% as a white solid 
(see Appendices 18-22), mp 82-83 0C. 1H NMR (500 MHz, DMSO-d6) δ 7.90 (d, J = 7.5 
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Hz, 2H; 2x Fmoc H Ar), 7.73 (t, J = 7.0 Hz, 2H; 2x Fmoc H Ar), 7.68 (d, J = 9.2 Hz, 1H; 
NH Fmoc), 7.42 (t, J = 7.4 Hz, 2H; 2x Fmoc H Ar), 7.32 (t, J = 7.0 Hz, 2H; 2x Fmoc H 
Ar), 4.77 (t, J = 9.3 Hz, 1H; NHCHCH2O), 4.48 – 4.38 (m, 2H; NCHCH2O), 4.35 (m, 
1H; NCHCH2OSi), 4.29 (d, J = 6.8 Hz, 2H; Fmoc CH2), 4.22 (t, J = 6.7 Hz, 1H; Fmoc 
CH), 3.83 (dd, J = 10.1, 5.6 Hz, 1H; NHCHCH2OSi), 3.74 (dd, J = 10.1, 7.4 Hz, 1H; 
NHCHCH2OSi), 3.68 (s, 3H; OCH3), 0.83 (s, 9H; (CH3)3CSi(CH3)2), 0.02 (s, 6H; 
(CH3)3CSi(CH3)2). 13C NMR (126 MHz, DMSO) δ 171.46; (CO)OCH3, 167.50; C=N 
(oxazoline), 156.3; OCONH, [144.26, 141.17]; C Fmoc Ar, 128.09, 127.50, 125.76, 
120.56]; CH Fmoc Ar , 69.92; CH2CH (oxazoline), 68.06; CH2CH (oxazoline), 66.31; 
Fmoc CH2, 63.24; CHCH2OSi, 52.61; OCH3, 51.67; CHCH2OSi, 47.06; Fmoc CH, 
26.10; (CH3)3CSi(CH3)2, 18.33; (CH3)3CSi(CH3)2, -5.00; (CH3)3CSi(CH3)2. 
 
3.3.2.4.2 Using DAST reagent 
Dipeptide (6) (1.5 g, 2.7 mmol) was dissolved in dry DCM (27 ml, 0.1 M), and the 
mixture was cooled to -78 0C under N2 atmosphere. DAST reagent (0.28 ml, 2.97 mmol) 
was added dropwise to the solution and stirred for 1h. Anhydrous K2CO3 (0.55 g, 4.05 
mmol) was added to the mixture in one portion and stirred for 1 h at the same 
temperature then for another h while allowing the reaction to warm to room temperature. 
The mixture was poured into saturated aqueous NaHCO3, and the aqueous layer was 
extracted with DCM twice. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by column chromatography using an 
EtOAc/hexane system to give the desired product (7) in a good yield 80%. NMR analysis 
as mentioned above. 
3.3.2.5 Synthesis of H2N-oxazole-OMe using DBU/BrCCl3 (8) 
Oxazoline (7) (1.2 g, 2.29 mmol) was dissolved in DCM (30 ml, 0.1M), and the mixture 
was cooled to 0 0C under N2 atmosphere. DBU (1.23 ml, 8.24 mmol) and BrCCl3 (0.82 
ml, 8.24 mmol) were added to the mixture dropwise. The reaction stirred at room 
temperature for 24 h, then the mixture was diluted with DCM. The organic layer was 
	  	   60	  
washed with H2O, brine, dried over MgSO4, filtered and the filtrate was concentrated in 
vacuo. The residue was purified by trituration with ether and the filtrate was concentrated 
to provide NH2-Oxazole-OMe (8) as a brown oil in 80% yield (see Appendix 23). 1H 
NMR (500 MHz, Methanol-d4) δ 8.72 (s, 1H; CH (oxazole)), 4.84-4.80 (m, 1H; 
NH2CHCH2OSi), 4.22 (dd, J = 16.9, 4.4 Hz, 1H; NH2CHCH2OSi), 3.92 (s, 3H; OCH3), 
3.90 (m, 1H; NH2CHCH2OSi), 0.88 (s, 9H; (CH3)3CSi(CH3)2), 0.08 (d, J = 14.0 Hz, 6H; 
(CH3)3CSi(CH3)2). 
3.3.2.6 One pot synthesis from dipeptide to H2N-oxazole-OMe 
using DAST reagent and DBU/ BrCCl3 (8) 
DAST reagent (0.35 ml, 3.51 mmol) was injected into a solution of dipeptide (6) (1.5 g, 
2.7 mmol) in DCM (27 ml, 0.1 M) at -78 0C under N2 atmosphere. After stirring for 1 h at 
the same temperature, TLC observations determined that the reaction was completed. 
DBU (1.3 ml, 8.8 mmol) was added to the mixture at -40 0C and stirred for 20 min. Then, 
BrCCl3 (0.86 ml, 8.8 mmol) was added at 0 0C and stirred overnight at room temperature. 
The mixture was then washed with H2O, dried over MgSO4 and filtered. The filtrate was 
concentrated in vacuo to leave a brown residue that was purified by trituration with 
hexane to provide the desired product (8) in 70%. NMR analysis as mentioned above. 
 
 
3.3.2.7 Synthesis of Fmoc-oxazole-OMe (9) 
3.3.2.7.1 Introducing Fmoc group to the H2N-oxazole-OMe  
H2N-Oxazole-OMe (8) (50 mg, 0.16 mmol) was dissolved in DMF (1.6 ml, 0.1 M), and 
the reaction mixture was cooled to 0 0C under a nitrogen atmosphere. Na2CO3 (33 mg, 
0.32 mmol) in H2O (1.6 ml) was added to the reaction. Then Fmoc-OSu (84 mg, 0.24 
mmol) in DMF (1.6 ml) was added at 0 0C and the mixture was stirred overnight at room 
temperature. The workup was completed by extraction with ether twice, and the aqueous 
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layer was acidified with 0.5 N NaHSO4 to pH=3 at 0 0C. Following this process, the 
aqueous layer was extracted with ether. The combined organic layer was washed with 
brine and dried over MgSO4. The crude was purified via column chromatography using 
an EtOAc/hexane system to give Fmoc-oxazole-OMe (9) as a white solid in 30% yield 
(see Appendices 24-28), mp 96-97 0C. 1H NMR (500 MHz, DMSO-d6) δ 8.85 (s, 1H; CH 
(oxazole)), 8.08 (d, J = 8.4 Hz, 1H; NH Fmoc), 7.89 (d, J = 7.5 Hz, 2H; 2x Fmoc H Ar), 
7.71 (t, J = 7.2 Hz, 2H; 2x Fmoc H Ar), 7.42 (t, J = 7.4 Hz, 2H; 2x Fmoc H Ar), 7.32 (t, J 
= 7.5 Hz, 2H; 2x Fmoc H Ar), 4.88 – 4.79 (m, 1H; NHCHCH2OSi), 4.32 (d, J = 7.0 Hz, 
2H; Fmoc CH2), 4.22 (t, J = 7.1 Hz, 1H; Fmoc CH), 3.99 (dd, J = 10.6, 7.0 Hz, 1H; 
NHCHCH2OSi), 3.91 (dd, J = 9.4, 7.2 Hz, 1H; NHCHCH2OSi), 3.81 (s, 3H; OCH3), 0.79 
(s, 9H; (CH3)3CSi(CH3)2), 0.00 (d, J = 8.9 Hz, 6H; (CH3)3CSi(CH3)2). 13C NMR (126 
MHz, DMSO) δ 163.52; (CO)OCH3, 161.50; C=N (oxazole), 156.31; OCONH, 146.05; 
HC=C (oxazole), [144.19, 141.18]; C Fmoc Ar , 132.70; HC=C (oxazole), [128.10, 
127.50, 125.68, 120.57]; CH Fmoc Ar , 66.33; Fmoc CH2, 63.33; CHCH2OSi, 52.27; 
OCH3, 51.54; CHCH2OSi, 47.05; Fmoc CH, 26.04; (CH3)3CSi(CH3)2, 18.26; 
(CH3)3CSi(CH3)2, -5.03; (CH3)3CSi(CH3)2. 
 
3.3.2.7.2 Using MnO2  
Oxazoline (7) (1.7 g, 3.25 mmol) was dissolved in anhydrous cyclohexane (19 ml). Then, 
activated MnO2 (8.5 g, mmol) and molecular sieves (100 Wt%) were added and the 
reaction mixture was stirred at 80 0C for 2 days. Following this process, the reaction 
mixture was filtered through a short Celite column and washed with EtOAc. The solvent 
was evaporated in vacuo and the resulting residue was purified by column 
chromatography using an EtOAc/hexane system to provide oxazole (9) in 20-40% yield 
as a pale yellow solid. NMR analysis as mentioned above. 
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3.3.2.7.3 Using CuBr and Cu(OAc)2 
CuBr (0.6 g, 4.19 mmol) and Cu(OAc)2 (0.76 g, 4.19 mmol) were added to the oxazoline 
(7) (2 g, 3.81 mmol) in a 50 ml round bottomed flask with three necks. The flask was 
evacuated and then filled with argon three times. Then, benzene (23.8 ml, 0.1 M) was 
syringed into the flask and the reaction was stirred and warmed at 60 0C. Tert-butyl 
perbenzoate (1.09 ml, 5.71 mmol) was added gradually over 15 minutes. Following this, 
the mixture was heated to reflux at 80 0C for 8 h. After the reaction mixture was cooled to 
room temperate, ethyl acetate (50 ml) was added and then washed with 10% NH4OH 
solution to remove the copper salts. The aqueous layer was extracted with ethyl acetate 
(3×50ml), and the organic extracts were collected and washed with H2O and brine.  Then 
the combined organic extract was dried over MgSO4 and the solvent was removed under 
reduced pressure. The crude product was subjected to column chromatography on SiO2 
using an EtOAc/hexane system (20:80) to give oxazole (9) as a pale yellow solid in 20-
43% yield. NMR analysis as mentioned above. 
  
 
 
3.3.2.8 Synthesis of Fmoc-oxazole-COOH (10) 
A solution of the Fmoc-oxazole-OMe (9) (1.8 g, 3.4 mmol) in i-PrOH/H2O (7:3, 0.1 M) 
was treated with NaOH (0.16 g, 4.0 mmol) and CaCl2 (0.95 g, 8.6 mmol). After stirring at 
room temperature for 6 h, the reaction mixture was neutralized with 1 N NaHSO4. The 
compound was extracted with EtOAc and the organic layer was washed first with H2O 
and then brine. Once this process was complete, the organic layer was dried over MgSO4, 
filtered and all of the solvent was evaporated in vacuo. The crude peptide acid (10) was 
obtained as a white solid in 70% yield and used in the next step without further 
purification (see Appendix 29). 1H NMR (500 MHz, Methanol-d4) δ 8.21 (s, 1H; CH 
(oxazole)), 7.80 (d, J = 7.4 Hz, 2H; 2x Fmoc H Ar), 7.70 – 7.61 (m, 2H; 2x Fmoc H Ar), 
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7.42 – 7.37 (t, J = 6.8 Hz, 2H; 2x Fmoc H Ar), 7.34 – 7.26 (m, 2H; 2x Fmoc H Ar), 5.01 
– 4.96 (m, 1H; NHCHCH2OSi), 4.60-4.58 (m, 1H; Fmoc CH), 4.45 – 4.32 (m, 2H; Fmoc 
CH2), 4.06 – 3.94 (m, 2H; NHCHCH2OSi), 0.84 (s, 9H; (CH3)3CSi(CH3)2), 0.03 (d, J = 
5.9 Hz, 6H; (CH3)3CSi(CH3)2). 
 
 
3.3.2.9 Synthesis of Fmoc-dioxazole-OMe (11) 
A solution of Fmoc-oxazole-COOH (10) (1.2 g, 2.4 mmol) in DCM (0.1 M, 24 ml) was 
treated with HBTU (1.07 g, 2.83 mmol) at room temperature. After that, the reaction 
mixture was cooled to 0 0C and DIEA (0.90 ml, 5.19 mmol) was added under a nitrogen 
atmosphere. After 5 minutes of stirring, NH2-oxazole-OMe (8) (0.70 g, 2.4 mmol) was 
added to the mixture and stirred at room temperature overnight. The solvent was 
evaporated and the resulting residue was dissolved in EtOAc and washed with 0.5 N 
NaHSO4, NaHCO3, H2O and brine. The organic layer was dried over MgSO4, filtered and 
concentrated under reduced pressure to obtain the crude. The crude was purified by 
column chromatography using an EtOAc/hexane system 60:40 to provide the dioxazole 
(11) as a white solid in 35-50% yield (see Appendices 30-33), mp 179-180 0C. 1H NMR 
(500 MHz, Methanol-d4) δ 8.50 (s, 1H; CH (oxazole)), 8.42 (s, 1H; CH (oxazole)), 7.80 
(d, J = 7.5 Hz, 2H; 2x Fmoc H Ar), 7.72 – 7.61 (m, 2H; 2x Fmoc H Ar), 7.38 (t, J = 7.1 
Hz, 2H; 2x Fmoc H Ar), 7.34 – 7.26 (m, 2H; 2x Fmoc H Ar), 5.41 (t, J = 5.1 Hz, 1H; 
NHCHCH2OSi), 4.99 (t, J = 5.7 Hz, 1H; NHCHCH2OSi), 4.41 (d, J = 6.2 Hz, 2H; Fmoc 
CH2), 4.23 (t, J = 6.8 Hz, 1H; Fmoc CH), 4.15 (dd, J = 7.3, 5.1 Hz, 2H; NHCHCH2OSi), 
4.10 – 3.96 (m, 2H; NHCHCH2OSi), 3.88 (s, 3H; OCH3), 0.85 (s, 18H; 2x 
(CH3)3CSi(CH3)2), 0.04 (d, J = 12.3 Hz, 12H; 2x (CH3)3CSi(CH3)2). 13C NMR (126 
MHz, MeOD) δ 162.99; (CO)OCH3, 162.78; CONH amide, 161.37; C=N (oxazole), 
161.00; C=N (oxazole), 156.83; OCONH, 144.89; HC=C (oxazole), 143.79; C Fmoc Ar,  
142.14; HC=C (oxazole), 141.20; C Fmoc Ar, 135.39; HC=C (oxazole), 132.87; HC=C 
(oxazole), [127.39, 126.75, 124.77, 119.55]; CH Fmoc Ar, 66.71; Fmoc CH2, 63.23; 
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CHCH2OSi, 51.46; CHCH2OSi, 51.13; OCH3, 49.29; Fmoc CH, 24.81; 
(CH3)3CSi(CH3)2, 17.58; (CH3)3CSi(CH3)2, -6.80; (CH3)3CSi(CH3)2. 
 
 
 
3.3.2.10 Synthesis of Fmoc-tetraoxazole-OMe  
3.3.2.10.1 The first route using two dioxazoles 
3.3.2.10.1.1 Synthesis of Fmoc-dioxazole-COOH (12) 
Once dioxazole (11) (0.16 g, 0,205 mmol) was dissolved in i-PrOH/H2O (7:3, 0.1 M), 
NaOH (0.01 g, 0.247 mmol) and CaCl2 (0.05 g, 0.512 mmol) were added to the mixture 
and stirred overnight at room temperature. The reaction was neutralized with 1 N 
NaHSO4 under an ice-bath to pH = 2, followed by extraction with EtOAc. The aqueous 
layer was re-extracted with EtOAc twice, and then the organic layers were collected and 
washed with H2O, brine, dried over MgSO4, and filtered. The filtrate was concentrated in 
vacuo to give a free acid (12) as a white solid in 70% yield (mp 195 0C), and the crude 
acid was used for the next reaction without further purification (see Appendix 34). 1H 
NMR (500 MHz, Methanol-d4) δ 8.42 (s, 2H; 2x CH (oxazole)), 7.81 (d, J = 6.4 Hz, 2H; 
2x Fmoc H Ar), 7.72 – 7.65 (t, J = 6.6 Hz, 2H; 2x Fmoc H Ar), 7.41 (t, J = 7.3 Hz, 2H; 
2x Fmoc H Ar), 7.35 – 7.28 (t, J = 7.2 Hz, 2H; 2x Fmoc H Ar), 5.46 – 5.38 (m, 1H; 
NHCHCH2OSi), 5.02 – 4.95 (m, 1H; NHCHCH2OSi), 4.43 (d, J = 6.9 Hz, 2H; Fmoc 
CH2), 4.28 – 4.20 (t, J = 6.4 Hz, 1H; Fmoc CH), 4.20 – 4.11 (m, 3H; NHCHCH2OSi), 
4.11 – 3.99 (m, 2H; NHCHCH2OSi), 0.86 (s, 19H; 2x (CH3)3CSi(CH3)2), 0.09 – 0.02 (m, 
12H; 2x (CH3)3CSi(CH3)2). 
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3.3.2.10.1.2 Synthesis of H2N-dioxazole-OMe (13) 
Once dioxazole (11) (0.15 g, 0.189 mmol) was dissolved in DCM (0.1 M, 2 ml), the 
mixture was cooled to 0 0C and DBU (0.05 ml, 0.378 mmol) was added to the mixture 
and left to stir overnight at room temperature. The mixture was diluted with DCM and 
washed with H2O. The aqueous layer was re-extracted with DCM, and the organic layers 
were washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in 
vacuo, and the crude amine (13) in 75% yield (mp 200 0C) that was used for the next step 
without purification (see Appendix 35). 1H NMR (500 MHz, Methanol-d4) δ 8.56 (s, 1H; 
CH (oxazole)), 8.42 (s, 1H; CH (oxazole)), 5.42 (t, J = 3.8 Hz, 1H; NHCHCH2OSi), 4.18 
(dd, J = 12.9, 4.8 Hz, 2H; NHCHCH2OSi), 4.15 – 4.09 (m, 1H; NHCHCH2OSi), 4.06 – 
3.93 (m, 2H; NHCHCH2OSi), 3.90 (s, 3H; OCH3), 0.87 (d, J = 8.5 Hz, 18H; 2x 
(CH3)3CSi(CH3)2), 0.12 – -0.06 (m, 12H; 2x (CH3)3CSi(CH3)2). 
 
 
3.3.2.10.1.3 Synthesis of Fmoc-tetraoxazole-OMe from two 
dioxazoles (14)  
A solution of Fmoc-dioxazole-COOH (12) (0.157 g, 0.20 mmol) in DCM (0.1 M, 2 ml) 
was treated with HBTU (0.1 g, 0.24 mmol) at room temperature. Following this, the 
reaction mixture was cooled to 0 0C and DIEA (0.06 ml, 0.44 mmol) was added under a 
nitrogen atmosphere. After being stirred for 5 minutes, NH2-dioxazole-OMe (13) (0.11 g, 
0.20 mmol) was added to the mixture and then stirred at room temperature for 12 h. The 
reaction mixture was concentrated and the resulting residue was dissolved in EtOAc and 
washed with 0.5 N NaHSO4, NaHCO3, H2O and brine. The organic layer was dried over 
MgSO4, filtered and concentrated under reduced pressure to obtain the crude. The crude 
was purified by column chromatography using an EtOAc/hexane system 60:40 to get the 
tetraoxazole (14) as a white solid in 80% yield (see Appendices 36-40), mp 180-190 0C. 
1H NMR (500 MHz, Chloroform-d) δ 8.28 – 8.13 (m, 4H; CH (oxazole)), 7.83 – 7.59 (m, 
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5H; 2x Fmoc H Ar, 3x NH amide), 7.42 (t, J = 7.1 Hz, 2H; 2x Fmoc H Ar), 7.33 (t, J = 
7.1 Hz, 2H; 2x Fmoc H Ar), 5.69 (d, J = 8.2 Hz, 1H; NH Fmoc), 5.46 (m, 3H; 3x 
NHCHCH2OSi), 5.08 (brd, 1H; NHCHCH2OSi), 4.45 (m, 2H; Fmoc CH2), 4.31 – 3.87 
(m, 13H; NHCHCH2OSi, Fmoc CH, OCH3), 0.94 – 0.78 (m, 37H; 4x (CH3)3CSi(CH3)2), 
0.12 – -0.05 (m, 24H; 4x (CH3)3CSi(CH3)2). 13C NMR (126 MHz, CDCl3) δ 163.11; 
(CO)OCH3, 162.34; CONH amide, 161.95; C=N (oxazole), 161.84; C=N (oxazole), 
161.51; C=N (oxazole), 160.19; C=N (oxazole), 155.74; OCONH, 144.05; HC=C 
(oxazole), 143.78; C Fmoc Ar, 143.56; C Fmoc Ar, 141.88; HC=C (oxazole), 141.77; 
HC=C (oxazole), 141.66; HC=C (oxazole), 141.31; HC=C (oxazole), 135.79; HC=C 
(oxazole), 135.66; HC=C (oxazole), 135.25; HC=C (oxazole), 133.53; HC=C (oxazole), 
[127.80, 127.08, 125.04, 120.07]; CH Fmoc Ar, 67.36 Fmoc CH2, 64.18; CHCH2OSi, 
63.99; CHCH2OSi, 63.89; CHCH2OSi, 63.79; CHCH2OSi, 52.24; OCH3, 51.52; 
CHCH2OSi, 49.15; CHCH2OSi, 49.05; CHCH2OSi, 48.96; CHCH2OSi, 47.11; Fmoc CH, 
25.66; (CH3)3CSi(CH3)2, 18.09; (CH3)3CSi(CH3)2, -5.50; (CH3)3CSi(CH3)2 . 
 
3.3.2.10.2 The second route to generate the tetraoxazole 
3.3.2.10.2.1 Synthesis of Fmoc-trioxazole-OMe (15)  
(0.627 g, 0.78 mmol) of Fmoc-dioxazole-COOH (12) and (0.364 g, 0.96 mmol) of HBTU 
were dissolved in dry DCM (0.1 M, 8 ml) at room temperature. The reaction mixture was 
then cooled to 0 0C and (0.3 ml, 1.76 mmol) of DIEA was added dropwise under argon. 
The mixture was stirred for 5 minutes, followed by the addition of H2N-monooxazole-
OMe (8) (0.23 g, 0.78 mmol). The reaction mixture was stirred for 1 h at 0 0C then 
overnight at room temperature. The mixture was diluted with DCM and washed with 0.5 
N NaHSO4, NaHCO3, H2O and brine. The organic layer was dried over MgSO4, filtered 
and the solvent was evaporated under reduced pressure to give the crude. The crude was 
purified by trituration with hot hexane to give the trioxazole (15) as a brown fine solid in 
75% yield (see Appendices 41-42), mp 245-250 0C. 1H NMR (500 MHz, Chloroform-d) 
δ 8.31 – 8.09 (brd s, 3H; 3x CH (oxazole)), 7.79 (brd, 3H; 2x Fmoc H Ar, NH amide), 
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7.70 – 7.59 (brd, 3H; 2x Fmoc H Ar, NH amide), 7.42 (brd, 3H; 2x Fmoc H Ar), 7.33 
(brd, 2H; 2x Fmoc H Ar), 5.70 (brd, 1H; NH Fmoc), 5.46 (brd, 1H; NHCHCH2OSi), 5.27 
(brd, 1H; NHCHCH2OSi), 5.09 (brd, 1H; NHCHCH2OSi), 4.45 (brd, 2H; Fmoc CH2), 
4.34 – 3.64 (m, 10H; 3x NHCHCH2OSi, Fmoc CH, OCH3), 1.02 – 0.63 (s, 27H; 3x 
(CH3)3CSi(CH3)2), 0.27 – -0.18 (m, 17H; 3x (CH3)3CSi(CH3)2). 13C NMR (126 MHz, 
CDCl3) δ 162.49; (CO)OCH3, 162.33; CONH amide, 161.41; C=N (oxazole), 160.15; 
C=N (oxazole), 160.07; C=N (oxazole), 155.18; OCONH, 143.63; C Fmoc Ar, 142.46; 
HC=C (oxazole), 141.82; HC=C (oxazole), 141.75; HC=C (oxazole), 141.30; C Fmoc 
Ar, 135.74; HC=C (oxazole), 133.46; HC=C (oxazole), 133.36; HC=C (oxazole), 
[127.78, 127.07, 125.02, 120.01]; CH Fmoc Ar, 67.40; Fmoc CH2, 64.15; CHCH2OSi, 
64.09; CHCH2OSi, 64.00; CHCH2OSi, 51.51; OCH3, 50.81; CHCH2OSi, 49.12; 
CHCH2OSi, 49.10; CHCH2OSi, 47.12; Fmoc CH, 25.66; (CH3)3CSi(CH3)2, 18.09; 
(CH3)3CSi(CH3)2, -5.54; (CH3)3CSi(CH3). 
 
 
3.3.2.10.2.2 Synthesis of Fmoc-trioxazole-COOH (16)  
(0.03 g, 0.68 mmol) of NaOH and (0.16 g, 1.4 mmol) of CaCl2 were added to a solution 
of trioxazole (15) in i-PrOH/H2O (7:3, 0.1 M) at room temperature and stirred overnight. 
Following this, the mixture was acidified with 1 N NaHSO4 and extracted with EtOAc 
three times. The organic layer was then dried over MgSO4, filtered, and concentrated. 
The crude acid (16) was obtained as a white solid in 72% yield that was used in the next 
step without further purification (see Appendix 43). 1H NMR (500 MHz, Chloroform-d) 
δ 8.32 – 8.13 (m, 3H; 3x CH (oxazole)), 7.79 (d, J = 6.8 Hz, 2H; 2x Fmoc H Ar), 7.65 
(m, 3H; 2x Fmoc H Ar, NH amide), 7.42 (t, J = 6.6 Hz, 3H; 2x Fmoc H Ar, NH amide), 
7.33 (t, J = 6.7 Hz, 2H; 2x Fmoc H Ar), 5.70 (brd, 1H, NH Fmoc), 5.49 (brd, 1H; 
NHCHCH2OSi), 5.27 (brd, 1H; NHCHCH2OSi), 5.09 (brd, 1H; NHCHCH2OSi), 4.46 (d, 
J = 7.6 Hz, 2H; Fmoc CH2), 4.14 (m, 6H; 3x NHCHCH2OSi), 3.93 (t, J = 7.6 Hz, 1H; 
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Fmoc CH), 1.03 – 0.65 (m, 27H; 3x (CH3)3CSi(CH3)2), 0.39 (s, 1H), 0.25 – -0.17 (m, 
17H; 3x (CH3)3CSi(CH3)2). 
 
3.3.2.10.2.3 Synthesis of Fmoc-tetraoxazole-OMe from 
trioxazole and monooxazole (14)  
HBTU (0.20 g, 0.53 mmol) was added to a solution of Fmoc-trioxazole-COOH (16) (0.44 
g, 0.41 mmol) in DCM (0.1 M, 4 ml). The mixture was cooled to 0 0C under a nitrogen 
atmosphere, and DIEA (0.1 ml, 0.9 mmol) was added dropwise and stirred for 5 minutes. 
(0.13 g, 0.41 mmol) amine H2N-monooxazole-OMe (8) was added and the reaction was 
stirred for 12 h at room temperature. The reaction mixture was diluted with DCM and 
washed with 0.5 N NaHSO4, NaHCO3, H2O and brine. The organic layer was dried over 
MgSO4, filtered, and concentrated under reduced pressure. The crude tetraoxazole was 
purified via column chromatography on SiO2 using an EtOAc/hexane system to provide 
the pure tetraoxazole (14) in 70% yield as a white solid. NMR data as mentioned above. 
3.3.2.11 Synthesis of Fmoc-tetraoxazole-COOH (17)  
Once tetraoxazole (14) (0.34 g, 0.25 mmol) was dissolved in i-PrOH/H2O (7:3, 0.1 M), 
NaOH (0.01 g, 0.3 mmol) and CaCl2 (0.07 g, 0.62 mmol) were added to the mixture and 
stirred overnight at room temperature. The reaction was neutralized with 1 N NaHSO4 
under an ice-bath to pH = 2, followed by extraction with EtOAc. The aqueous layer was 
re-extracted with EtOAc twice, and then the organic layers were collected and washed 
with H2O, brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo 
to provide a free acid (17) as a white solid in 75% yield, and the crude acid was used for 
the next reaction without further purification.  
3.3.2.12 Synthesis of H2N-tetraoxazole-COOH (18) 
Fmoc-tetraoxazole-COOH (17)  (0.16 g, 0.205 mmol) was dissolved in DCM (2 ml, 0.1 
M) and the mixture was cooled to 0 0C. DBU (0.112 g, 0.22 mmol) was then added and 
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the mixture was left to stir overnight at room temperature. The mixture was diluted with 
DCM and washed with H2O. Next, the aqueous layer was re-extracted with DCM, and 
the organic layers were washed with brine, dried over MgSO4, and filtered. The filtrate 
was concentrated in vacuo, and the unprotected tetraoxazole, H2N-tetraoxazole-COOH 
(18) in 76% yield, was used for the next step without purification (see Appendix 44). 1H 
NMR (500 MHz, Chloroform-d) δ 11.14 (s, 1H; COOH), 8.30 – 8.13 (brd, 4H; 4x CH 
(oxazole)), 7.53 (d, J = 7.0 Hz, 2H; 2x NH amide), 7.49 (d, J = 7.2 Hz, 1H; NH amide), 
5.57 – 5.33 (brd, 2H; NHCHCH2OSi), 5.33 – 5.12 (brd, 2H; NHCHCH2OSi), 1.02 – 0.54 
(m, 36H; 4x (CH3)3CSi(CH3)2), 0.21 – -0.29 (m, 24H; 4x (CH3)3CSi(CH3)2). 
 
3.3.2.13 Synthesis of the macrocycle tetraoxazole (19)  
A solution of the deprotected peptide (18) (0.15 g, 0.14 mmol) in dry DMF (70 ml) was 
added dropwise to a solution of PyOxim (0.08 g, 0.15 mmol) and base DIEA (0.1 ml, 
0.44 mmol) in dry DMF (70 ml) at room temperature under a nitrogen atmosphere and 
stirred for 3 days. The solvent was evaporated under reduced pressure, and then the 
residue was diluted with DCM. The mixture was washed with 1 N NaHSO4, saturated 
NaHCO3, water, and brine. The organic layer was dried over MgSO4, filtered, and 
evaporated in vacuo. The crude was purified by column chromatography using an 
EtOAc/hexane system, to provide the desired compound (19) as a yellow oil in 20% yield 
(see Appendix 45). 1H NMR (500 MHz, Chloroform-d) δ 8.21 (m, 4H; 4x CH (oxazole)), 
7.69 (brd, 4H; 4x NH amide), 5.51 – 5.37 (m, 4H; 4x NHCHCH2OSi), 3.40 – 3.29 (m, 
4H; 4x NHCHCH2OSi), 3.11 – 3.04 (dd, J = 12.9, 3.35 Hz 2H; 2x NHCHCH2OSi), 3.00 
(m, 2H; 2x NHCHCH2OSi), 0.99 – 0.71 (m, 36H; 4x (CH3)3CSi(CH3)2), 0.19 – -0.17 (m, 
24H; 4x (CH3)3CSi(CH3)2). 
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3.4 Synthesis of the tetraoxazole macrocyclic peptide with t-Bu 
groups 
3.4.1 Synthesis of the dimer Boc-Cys(t-Bu)-OH-Ser-OMe (20) 
A solution of Boc-L-Cys(t-Bu)-OH (5.0 g, 18 mmol) in DCM (180 ml, 0.1 M) was 
treated with HBTU (8.87 g, 23.3 mmol, 1.2eq) at room temperature. The flask was placed 
under a nitrogen atmosphere, and the mixture was cooled to 0 0C. DIEA (10.9 ml, 62.9 
mmol) was then added and the mixture was stirred for 5 minutes followed by the addition 
of H-Ser-L-OMe.HCl (2.80 g, 18 mmol). The resulting mixture was stirred overnight at 
room temperature and then diluted with DCM, and washed with 0.5 N NaHSO4. The 
aqueous layer was re-extracted with DCM and the organic layers were collected and 
washed with NaHCO3, H2O and brine. The organic layer was then dried over MgSO4, 
filtered and concentrated in vacuo. Finally, the crude was purified by crystallization with 
hot hexane at 40 0C overnight to provide the dipeptide (20) as a white solid in 100% yield 
(see Appendices 46-47), mp 145-146 0C. 1H NMR (500 MHz, Chloroform-d) δ 7.20 (d, J 
= 7.3 Hz, 1H; NH amide), 5.42 (brd, 1H; NH Boc), 4.64 (m, 1H; αCHCys), 4.29 (m, 1H; 
αCH Ser), 4.07 – 3.98 (dd, J = 11, 3.6 Hz 1H; CH2 Ser), 3.95 (dd, J = 11.5, 3.6 Hz, 1H; 
CH2 Ser), 3.81 (s, 3H; OCH3), 3.03 (dd, J = 12.7, 6.4 Hz, 1H; CH2 Cys), 2.92 (dd, J = 
12.8, 5.7 Hz, 1H; CH2 Cys), 1.47 (s, 10H; (CH3)3 Boc), 1.35 (s, 9H; (CH3)3 t-Bu).13C 
NMR (126 MHz, CDCl3) δ 170.82; (CO)OCH3, 170.48; CONH amide, 155.64; 
C(CH3)3OCO Boc , 80.73; C(CH3)3OCO Boc, 62.59; CH2 Ser, 55.09; αC Cys, 54.54; αC 
Ser, 52.77; (CO)OCH3, 42.97; C(CH3)3 t-Bu, 30.85; C(CH3)3 t-Bu, 30.42; CH2 Cys, 
28.26; C(CH3)3OCO Boc. 
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3.4.2 Synthesis of Boc-oxazole-OMe (21) 
3.4.2.1 Synthesis of Boc-oxazoline-OMe  
(6.8 g, 17.9 mmol) of dipeptide (20) was dissolved in dry DCM (0.1 M, 180 ml) and 
cooled to -78 0C under N2. DAST reagent (2.62 ml, 26.81 mmol) was added dropwise 
over 15 min to the solution and left to stir for 2 h. (4.94 g, 35.74 mmol) of anhydrous 
K2CO3 was then added to the mixture in one portion and stirred for 1 h at the same 
temperature than for another h allowing the reaction to warm to room temperature. Based 
on the observations of the TLC, the reaction was complete. The reaction mixture was 
poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with DCM 
twice. The combined organic layer was dried over MgSO4, filtered and concentrated in 
vacuo. The residue was used in the next step without further purification. 
3.4.2.2 Synthesis of Boc-oxazole-OMe  
DBU (5.35 ml, 35.79 mmol) was added to a solution of crude oxazoline in DCM (0.1 M, 
180 ml) at 0 0C under a nitrogen atmosphere. After being stirred for 5 min, BrCCl3 (3.52 
ml, 35.75 mmol) was added at the same temperature. The reaction was stirred for 1 h at 0 
0C and then left to stir at room temperature overnight. The reaction mixture was diluted 
with DCM and washed with NH4Cl. The aqueous layer was re-extracted with DCM, and 
the combined organic layer was washed with brine, dried over MgSO4, and filtered. After 
the solvent was removed under reduce pressure, the residue was purified by column 
chromatography on SiO2 with EtOAc/hexane system to give the monooxazole (21) as a 
white solid in 48 % yield in 3 steps (see Appendices 48-49), mp 120-121 0C.1H NMR 
(500 MHz, Chloroform-d) δ 8.21 (s, 1H; CH= (Oxazole)), 5.49 (brd, 1H; NH Boc), 5.17 
(brd, 1H; αCHCys), 3.93 (s, 3H; OCH3), 3.13 (dd, J = 13.3, 5.4 Hz, 1H; CH2 Cys), 3.07 
(dd, J = 13.1, 6.2 Hz, 1H; CH2 Cys), 1.45 (s, 9H; (CH3)3 Boc), 1.31 (s, 9H; (CH3)3 t-
Bu).13C NMR (126 MHz, CDCl3) δ 164.08; (CO)OCH3, 161.43; C=N(Oxazole), 154.69; 
C(CH3)3OCO Boc, 144.09; CH=C (Oxazole), 133.37; CH=C (Oxazole), 80.35; 
C(CH3)3OCO Boc, 52.22; COOCH3, 49.17; αC Cys, 42.85; C(CH3)3 t-Bu, 32.55; CH2 
Cys , 30.88; C(CH3)3 t-Bu, 28.27; C(CH3)3OCO Boc. 
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3.4.3 Synthesis of Boc-oxazole-COOH using LiOH (22) 
The protected monooxazole (21) (1.5 g, 4.19 mmol) was dissolved in THF (0.1 M, 42 ml) 
and the solution was cooled to 0 0C under a nitrogen atmosphere. LiOH.H2O (0.351 g, 
8.38 mmol) in H2O (0.1 M, 42 ml) was added dropwise over 15 min at 0 0C. After the 
reaction being stirred for 3 h, THF was evaporated and the residue was diluted with 
water. The reaction mixture was acidified with 1 N HCl at 0 0C to the PH=3 and extracted 
with EtOAc twice.  The organic layers were combined and washed with brine, dried over 
MgSO4 and filtered. The organic solvent was removed under reduced pressure to give the 
free acid (22) as a yellow solid in 45% yield (see Appendices 50-51), mp 137-139 0C. 1H 
NMR (500 MHz, Chloroform-d) δ 8.30 (s, 1H; CH= (Oxazole)), 5.73 (brd, 1H; NH Boc), 
5.21 (brd, 1H; αCHCys), 3.13 (dd, J = 12.5, 5.0 Hz, 1H; CH2 Cys), 3.09 (dd, J = 12.8, 6.4 
Hz, 1H; CH2 Cys), 1.46 (s, 9H; (CH3)3 Boc ), 1.32 (s, 9H; (CH3)3 t-Bu). 13C NMR (126 
MHz, CDCl3) δ 164.65; (CO)OH, 163.97; C=N(Oxazole), 154.96; C(CH3)3OCO Boc , 
145.00; CH=C (Oxazole), 132.84; CH=C (Oxazole), 80.44; C(CH3)3OCO Boc, 49.21; αC 
Cys, 42.92; C(CH3)3 t-Bu, 32.43; CH2 Cys, 30.88; C(CH3)3 t-Bu, 28.28; C(CH3)3OCO 
Boc. 
 
3.4.4 Synthesis of HCl.H2N-oxazole-OMe (23) 
(1.5 g, 4.19 mmol) of the monooxazole (21) was dissolved in dry THF (0.3 M, 13 ml) and 
the mixture was cooled to 0 0C under a nitrogen atmosphere. (34.5 ml, 138 mmol) of 4 M 
HCl/1,4 dioxane was added to the mixture and stirred for 2 h at room temperature. The 
solvent was evaporated in vacuo, and the oily residue was washed with dry ether. A 
simple decantation was used to give the free amine (23) as a salt in a quantitative yield 
(see Appendices 52-53), mp 97-99 0C. 1H NMR (500 MHz, Methanol-d4) δ 8.70 (s, 1H; 
CH= (Oxazole)), 4.82 (m, 1H; αCHCys), 3.92 (s, 3H; OCH3), 3.27 (m, 1H; CH2 Cys), 
3.22 (dd, J = 13.4, 6.9 Hz, 1H; CH2 Cys), 1.36 (s, 9H; (CH3)3 t-Bu). 13C NMR (126 MHz, 
MeOD) δ 161.22; (CO)OCH3, 159.70; C=N (Oxazole), 145.97; CH=C (Oxazole), 
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133.28; CH=C (Oxazole), 51.37; COOCH3, 48.79; αC Cys, 43.11; C(CH3)3 t-Bu, 29.65; 
C(CH3)3 t-Bu, 29.32;  CH2 Cys. 
 
3.4.5 Synthesis of Boc-dioxazole-OMe (24) 
A solution of free acid Boc-oxazole-COOH (22) (0.47 g, 1.4 mmol) in DCM (0.1 M, 14.3 
ml) was treated with HBTU (0.65 g, 1.7 mmol) at room temperature. After that, the 
reaction mixture was cooled to 0 0C and DIEA (0.8 ml, 4.5 mmol) was added under a 
nitrogen atmosphere. After 5 minutes of stirring, HCl.H2N-Oxazole-OMe (23) (0.4 g, 1.4 
mmol) was added to the mixture and stirred at room temperature overnight. The mixture 
was diluted with DCM and washed once each with 1 N NaHSO4, saturated NaHCO3, 
H2O, and brine. The organic layer was dried over MgSO4, filtered, and concentrated in 
vacuo. The resulting crude was purified by column chromatography using an 
EtOAc/hexane system to afford the desired compound (24) as a yellow oil in 80% yield 
(see Appendices 54-55). 1H NMR (500 MHz, Chloroform-d) δ 8.22 (s, 1H; CH= 
(Oxazole)), 8.16 (s, 1H; CH= (Oxazole)), 7.63 (d, J = 9.2 Hz, 1H; NH amide), 5.61 (m, 
1H; NH Boc), 5.39 (brd, 1H; αCHCys), 5.14 (brd, 1H; αCHCys), 3.94 (s, 3H; OCH3), 
3.25 (dd, J = 13.4, 6.05 Hz, 1H; CH2 Cys), 3.18 (dd, J = 13.1, 6.85 Hz, 1H; CH2 Cys), 
3.15 – 2.98 (m, 2H; CH2 Cys), 1.48 (s, 9H; (CH3)3 Boc), 1.35 (m, 21H; 2x(CH3)3 t-Bu). 
13C NMR (126 MHz, CDCl3) δ 163.46; (CO)OCH3, 163.01; CONH amide, 161.39; 
C=N(Oxazole), 159.86; C=N(Oxazole), 154.83; C(CH3)3OCO Boc, 144.17; CH=C 
(Oxazole), 141.81; CH=C (Oxazole) , 135.46; CH=C (Oxazole), 133.56; CH=C 
(Oxazole), 133.56; CH=C (Oxazole), 80.49; C(CH3)3OCO Boc, 52.26; COOCH3, 49.09; 
αC Cys, 47.48; αC Cys, 43.17; C(CH3)3 t-Bu, 42.90; CH2 Cys, 32.22; CH2 Cys, 30.95; 
C(CH3)3 t-Bu, 28.31; C(CH3)3OCO Boc. 
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3.4.6 Synthesis of Boc-dioxazole-COOH (25)  
The dioxazole (24) (0.616 g, 1.1 mmol) was dissolved in THF (0.1 M, 11 ml), and the 
mixture was cooled to 0 0C under N2 atmosphere. (0.1 g, 2.2 mmol) of LiOH.H2O in H2O 
(0.1 M, 11 ml) was added dropwise to the mixture, and the mixture was stirred for 4 h at 
room temperature. THF was evaporated under reduced pressure and water was added to 
the mixture. The mixture was acidified with 1N HCl to pH=3, and then extracted with 
EtOAc three times. The combined organic layer was washed with brine, dried over 
MgSO4, and evaporated to dryness to give the acid (25) as a white solid in 75% yield (see 
Appendices 56-57), mp 140-142 0C. 1H NMR (500 MHz, Chloroform-d) δ 8.29 (s, 1H; 
CH= (Oxazole)), 8.20 (s, 1H; CH= (Oxazole)), 7.69 (d, J = 7.4 Hz, 1H; NH amide), 5.62 
(d, J = 7.0 Hz, 1H; NH Boc), 5.44 (brd, 1H; αCHCys), 5.16 (brd, 1H; αCHCys), 3.26 (dd, 
J = 13.65, 5.45 Hz, 2H; CH2 Cys), 3.22-3.15 (dd, J = 13.65, 6.7 Hz 2H; CH2 Cys), 1.48 
(s, 9H; (CH3)3 Boc), 1.39 – 1.24 (m, 18H; 2x(CH3)3 t-Bu). 13C NMR (126 MHz, CDCl3) δ 
163.52; (CO)OH, 163.10; (CO)NH, 159.98; C=N(Oxazole), 154.89; C(CH3)3OCO Boc, 
145.02; CH=C (Oxazole), 145.02; CH=C (Oxazole) 135.37; CH=C (Oxazole), 133.02; 
CH=C (Oxazole), 80.56; C(CH3)3OCO Boc, 49.08; αC Cys, 47.50; αC Cys, 43.20; 
C(CH3)3 t-Bu, 42.92; CH2 Cys, 32.22; CH2 Cys, 30.89; C(CH3)3 t-Bu, 28.31; 
C(CH3)3OCO Boc. 
 
3.4.7 Synthesis of Boc-trioxazole-OMe (26)  
(0.440 g, 0.77 mmol) of Boc-dioxazole-COOH (25) was dissolved in DCM (0.1 M, 8 ml) 
and the mixture was cooled to 0 0C under argon. Amine, HCl.H2N-oxazole-OMe (23), 
(0.22 g, 0.77 mmol), EDC.HCl (0.18 g, 0.96 mmol), and HOBt (0.13 g, 0.96 mmol) were 
added successively to the reaction mixture. The mixture was stirred for 5 minutes, 
followed by the addition of DIEA (0.33 ml, 1.9 mmol). The reaction mixture was stirred 
for 1 h at 0 0C then overnight at room temperature. The mixture was diluted with DCM 
and washed with 0.5 N NaHSO4, NaHCO3, H2O and brine. The organic layer was dried 
over MgSO4, filtered, and concentrated in vacuo. The crude was purified by 
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crystallization using hot hexane to give trioxazole (26) as a brown solid in 85 % yield 
(see Appendices 58-59), mp 108-111 0C. 1H NMR (500 MHz, Chloroform-d) δ 8.23 (s, 
1H; CH= (Oxazole)), 8.20 (m, 2H; 2xCH= (Oxazole)), 7.65 (d, J = 8.7 Hz, 1H; NH 
amide), 7.55 (d, J = 8.5 Hz, 1H; NH amide), 5.65-5.53 (m, 2H; NH Boc, αCHCys), 5.41 
(brd, 1H; αCHCys), 5.15 (brd, 1H; αCHCys), 3.93 (s, 3H; OCH3), 3.28 – 3.03 (m, 6H; 3x 
CH2 Cys), 1.47 (s, 9H; (CH3)3 Boc), 1.38 – 1.30 (m, 27H; 3x(CH3)3 t-Bu). 13C NMR (126 
MHz, CDCl3) δ 163.44; (CO)OCH3, 163.01; (CO)NH, 162.23; C=N(Oxazole), 161.38; 
C=N(Oxazole), 159.87; C=N(Oxazole), 154.84; C(CH3)3OCO Boc, 144.18; CH=C 
(Oxazole), 141.99; CH=C (Oxazole), 141.87; CH=C (Oxazole), 135.65; CH=C 
(Oxazole), 135.47; CH=C (Oxazole), 133.53; CH=C (Oxazole), 80.47; C(CH3)3OCO 
Boc, 52.24; COOCH3, 49.11; αC Cys, 47.51; αC Cys, 47.39; αC Cys, 43.16; C(CH3)3 t-
Bu, 42.89; CH2 Cys, 32.16; CH2 Cys, 31.78; CH2 Cys, 30.95; C(CH3)3 t-Bu, 28.30; 
C(CH3)3OCO Boc. 
 
3.4.8 Synthesis of Boc-trioxazole-COOH (27)  
(0.05 g, 1.3 mmol) of LiOH.H2O in H2O (0.1 M, 6.5 ml) was added dropwise to a 
solution of trioxazole (26) (0.6 g, 0.65 mmol) in THF (0.1 M, 6.5 ml) at 0 0C under 
nitrogen. The mixture was stirred for 1 h at 0 0C then allowed to warm up to room 
temperature. Upon completion, THF was evaporated and water was added to the mixture. 
The mixture was acidified with 1 N NaHSO4 to pH= 2 at 0 0C and extracted with EtOAc 
three times. The organic layers were combined and dried over MgSO4, filtered, and 
concentrated in a vacuo to give the free acid (27) as a yellow solid in 91% yield (see 
Appendix 60), mp 156-157 0C. 1H NMR (500 MHz, Chloroform-d) δ 8.32-8.06 (m, 1H; 
CH= (Oxazole), 7.78-7.48 (brd, 1H; NH amide), 5.52 (m, 3H; 2x αCHCys, NH Boc), 
5.12 (brd, 1H; αCHCys), 3.09 (m, 6H; 3x CH2 Cys), 1.47 (s, 10H; (CH3)3 Boc), 1.34 (m, 
28H; 3x(CH3)3 t-Bu ).  
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3.4.9 Synthesis of Boc-tetraoxazole-OMe (28)  
To a cold solution of Boc-trioxazole-COOH (27) (0.5 g, 0.6 mmol) in DCM (0.1 M, 6 
ml) was added HCl.H2N-oxazole-OMe, (0.17 g, 0.6 mmol), EDC.HCl (0.14 g, 0.75 
mmol), and HOBt (0.1 g, 0.75 mmol). The mixture was stirred for 5 min, then DIEA (0.3 
ml, 1.5 mmol) was added slowly. The reaction mixture was stirred for 1 h at 0 0C then 
overnight at room temperature. The reaction mixture was diluted with DCM and washed 
with 0.5 N NaHSO4, NaHCO3, H2O and brine. The organic layer was dried over MgSO4, 
filtered, and concentrated under reduced pressure. The crude was purified by column 
chromatography on SiO2 using an EtOAc/hexane system to give the tetraoxazole (28) as a 
white solid in 30% yield (see Appendices 61-62). 1H NMR (500 MHz, Chloroform-d) δ 
8.23 – 8.16 (m, 4H; 4xCH= (Oxazole)), 7.74 (m, 1H; NH amide), 7.62 (d, J = 8.1 Hz, 1H; 
NH amide), 7.57 (d, J = 8.2 Hz, 1H; NH amide), 5.62 – 5.52 (m, 3H; 3x αC Cys), 5.43 
(brd, 1H; αC Cys), 5.18 – 5.08 (d, J = 7.1 Hz, 1H; NH Boc), 3.91 (s, 3H; OCH3), 3.26 – 
3.05 (m, 8H; 4x CH2 Cys), 1.44 (s, 12H; (CH3)3 Boc), 1.36 – 1.28 (m, 39H; 4x(CH3)3t-
Bu). 13C NMR (126 MHz, CDCl3) δ 162.95; (CO)OCH3, 162.55; (CO)NH, 161.30; 
C=N(Oxazole), 160.48; C=N(Oxazole), 160.37; C=N(Oxazole), 160.12; C=N(Oxazole), 
155.10; C(CH3)3OCO Boc, 144.50; CH=C (Oxazole), 142.56; CH=C (Oxazole), 142.49; 
CH=C (Oxazole), 142.42; CH=C (Oxazole), 135.50; CH=C (Oxazole), 133.43; CH=C 
(Oxazole), 80.56; C(CH3)3OCO Boc, 52.21; COOCH3, 48.79; αC Cys, 47.65; αC Cys, 
47.24; αC Cys, 46.98; αC Cys, 45.89; CH2 Cys, 44.36; CH2 Cys, 44.26; CH2 Cys, 42.91; 
C(CH3)3, t-Bu, 30.90; C(CH3)3 t-Bu, 29.66; CH2 Cys, 28.24; C(CH3)3OCO Boc. 
  
 
 
3.4.10 Synthesis of Boc-tetraoxazole-COOH (29) 
Once Boc-tetraoxazole-OMe (28) (0.08 g, 0.085 mmol) was dissolved in THF (0.1 M, 1 
ml), LiOH.H2O (0.01 g, 0.17 mmol) in H2O (0.1 M, 1 ml) was added to the mixture at 0 
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0C under a nitrogen atmosphere. The mixture was stirred for 6 h at room temperature. 
THF was evaporated and the mixture was acidified with 1 N HCl at 0 0C. The aqueous 
layer was extracted with EtOAc twice. The combined organic layer was washed with 
brine, dried over MgSO4, filtered and concentrated in vacuo. The free acid, Boc-
tetraoxazole-COOH (29) was obtained in 90% yield and used in the next step without 
further purification.  
3.4.10 Synthesis of HCl.H2N-tetraoxazole-COOH (30) 
The free acid, Boc-tetraoxazole-COOH (29) (0.08 g, 0.085 mmol) was dissolved in dry 
THF (0.3 M, 0.3 ml) and the mixture was cooled to 0 0C under a nitrogen atmosphere. 
(0.7 ml, 2.80 mmol) of 4 M HCl/1,4 dioxane was added and the reaction mixture was 
stirred for 8 h at room temperature. The solvent was evaporated in vacuo. Then, the 
residue was washed with dry ether, and collected by filtration to provide the free amine 
(30) as a salt in 81% yield (see Appendix 63). 1H NMR (500 MHz, Methanol-d4) δ 8.57 
(s, 4H; 4xCH= (Oxazole)), 5.11 (brd, 3H; 3x αC Cys), 4.20 (m, 1H; αC Cys), 2.42 (m, 
9H; 2xCH2 Cys). 
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Chapter 4- Conclusion and outlook 
The main emphasis of this study has been to establish a methodology to synthesize new 
tetraoxazole macrocyclic peptides through solution phase peptide synthesis. The 
synthesis of the tetraoxazole macrocyclic peptide with TBS groups was demonstrated. 
After the formation of the dipeptide, the oxazole ring was obtained by cyclodehydration 
followed by oxidation.  Different synthetic routes for the synthesis of the linear 
tetraoxazole were developed; the convergent approach and the stepwise approach. The 
final macrocyclization step of the unprotected linear tetraoxazole precursor was 
accomplished by utilizing the coupling reagent PyOxim under very dilute conditions. 
Although the target macrocycle was obtained, it was difficult to obtain a pure compound 
even after purification by column chromatography on SiO2.  
Because of the low yield of the fully protected monooxazole, changing the starting 
materials as well as the protecting group to Boc and t-Bu was done in order to optimize 
the yield, thus allowing for the synthesis of the tetraoxazole macrocyclic peptide with t-
Bu groups. In the synthesis of the tetraoxazole macrocyclic peptide with t-Bu groups, the 
yield of the fully protected monooxazole is much higher than that for the synthesis of 
tetraoxazole macrocyclic peptide with TBS. In addition, the formation of the di, tri-, as 
well as the tetraoxazoles was preformed easily. After the formation of fully protected 
tetraoxazole, the methyl ester group was removed successfully. However, when the Boc 
group was removed using 4 M HCl in dioxane, the t-Bu group was also cleaved. As a 
result, the macrocyclization of the linear tetraoxazole could not be performed.  
It would be interesting to scale-up the reaction for the synthesis of the tetraoxazole 
macrocyclic peptides, and complete the synthesis of tetraoxazole macrocyclic peptide 
with t-Bu groups. The Boc group needs to be removed carefully to avoid the cleavage of 
the t-Bu group. Alternatively, in case of t-Bu cleavage, the thiol group could be 
reprotected prior to cyclization.  
The tetraoxazole macrocyclic peptide with TBS groups, unfortunately, was not tested for 
metal complexation due to impurity. In addition, there were a lot of challenges with the 
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chemical synthesis of the target compound. However, in using the Boc and t-Bu 
protecting groups, the yields of the intermediate compounds needed to form the 
tetraoxazole macrocyclic peptide were improved.  Once the macrocycle is obtained, 
perhaps high-performance liquid chromatography could be used to purify the compound, 
the metal complexation could be evaluated.  
With structural similarities to the macrocyclic peptides derived from the marine sources, 
the tetraoxazole macrocyclic peptide with TBS groups might be utilized as a chelating 
agent to remove metals. Furthermore, the side chain in the tetraoxazole macrocyclic 
peptide can be changed to a variety of functional groups; thus, different derivatives can 
be generated from it without altering the ring structure by the modification of the side 
chain. In theory, after deprotecting the TBS group using acid or fluoride, different groups 
can be introduced to the tetraoxazole macrocyclic peptide. Therefore, the synthesis of 
different derivatives of tetraoxazole macrocyclic peptides can be performed.  
In addition, the side chain in the tetraoxazole macrocyclic peptide, which is OTBS, can 
allow the formation of an octaoxazole macrocycle. After the removal of the protecting 
group, the side chains of the amino acid can be used for four cyclodehydration reactions 
in a single step, followed by oxidation reaction. Thus, providing the octa-oxazole 
macrocycle which potentially could serve an analog to telomestatin. With the structural 
similarity to telomestatin, the compound could be used as an anticancer therapeutic agent 
that targets the G-quadruplex. Studies could be performed to test these hypotheses, along 
with the investigation of metal complexation properties. 
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Appendix-Supporting Spectra for Chapter 2 
 
 
Appendix 1: 1H NMR Boc-Ser-OH(O-TBS) (1). 
* Peaks at at 1.24, 2.01 and 4.10 ppm due to EtOAc solvent. * Peak at1.5 ppm 
due to water. 
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Appendix 2: 13C NMR Boc-Ser-OH(O-TBS) (1). 
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Appendix 3: 1H NMR N-Boc-Ser(O-TBS)-Ser-OMe (2). 
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Appendix 4: 13C NMR N-Boc-Ser(O-TBS)-Ser-OMe (2). 
* Peaks at 14, 22, and 31 ppm due to hexane solvent 
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Appendix 5: 1H NMR H2N-Ser-OH-Ser-OMe (3). 
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Appendix 6: 13C NMR H2N-Ser-OH-Ser-OMe (3). 
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Appendix 7: 1H NMR Ser-OH(O-TBS) (4). 
* Peaks at 7.3 and 8.3 ppm due to impurities from the reagent imidazole. 
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Appendix 8: 13C NMR Ser-OH(O-TBS) (4). 
* Impurities from the reagent imidazole 
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Appendix 9: 1H NMR Fmoc-Ser-OH(O-TBS) (5). 
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Appendix 10: 13C NMR Fmoc-Ser-OH(O-TBS) (5). 
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Appendix 11: DEPT 135 NMR Fmoc-Ser-OH(O-TBS) (5). 
 
 
Appendix 12: DEPT 90 NMR Fmoc-Ser-OH(O-TBS) (5). 
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Appendix 13: 1H NMR Fmoc-Ser(O-TBS)-Ser-OMe (6). 
* Peaks at 1.2 ppm due to EtOAc solvent 
The singlet peak at 3.8 ppm represents the methyl ester group (OCH3) and CH2 and CH 
as multiplets at 4.04-3.9 ppm and 4.69 ppm respectively from the serine methyl ester. 
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Appendix 14: COSY NMR Fmoc-Ser(O-TBS)-Ser-OMe (6). 
2-Dimension NMR correlation spectroscopy (COSY) of proton-proton correlation 
analysis was done to identify the coupling between neighbouring protons. The square 
pattern represents the coupling between those specific peaks from the 1D proton NMR 
spectra on the X and Y axis of the 2D matrix. 
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Appendix 15: 13 C NMR Fmoc-Ser(O-TBS)-Ser-OMe (6). 
Distortionless enhancement by polarization transfer (DEPT) 135 and DEPT 90 was done 
to identify carbon peaks. DEPT determine the number of hydrogens attached to each 
carbon in a compound. DEPT 135 yields CH and CH3 as positive peaks whereas CH2 as 
negative signals. DEPT 90 gives only CH peaks and quaternary carbon peaks are 
disappeared in both DEPT 135 and DEPT 90. 
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Appendix 16: DEPT 135 NMR Fmoc-Ser(O-TBS)-Ser-OMe (6). 
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Appendix 17: DEPT 90 NMR Fmoc-Ser(O-TBS)-Ser-OMe (6). 
 
The presence of small peak for the CH3 single at 25 ppm in the DEPT 90 spectrum that 
should zero intensity instead because of the leakage that can happen. Leakage can occur 
from incorrectly calibrated pulse width for the spectrometer. 
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Appendix 18: 1H NMR Fmoc-oxazoline-OMe (7). 
* Peak at 3.4 ppm due to the by-product from Burgess reagent and it is 55 ppm in 13C 
* Peak at 5.6 due to DCM solvent 
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Appendix 19: COSY NMR Fmoc-oxazoline-OMe (7). 
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Appendix 20: 13C NMR Fmoc-oxazoline-OMe (7). 
* Peak at 55 ppm due to by-product from Burgess reagent 
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Appendix 21: DEPT 135 NMR Fmoc-oxazoline-OMe (7). 
 
 
Appendix 22: DEPT 90 NMR Fmoc-oxazoline-OMe (7). 
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Appendix 23: 1H NMR H2N-oxazole-OMe (8). 
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* Peaks at 0.99 and 1.32 ppm for the hexane solvent and 2.1 ppm for acetone solvent. 
The 1H NMR data shows the expected signal of the aromatic proton at δ 8.72 ppm (s, 1H; 
OCH=C) that confirmed the formation of oxazole ring. Also, it confirmed the deprotection 
of the Fmoc group by the disappearance of the Fmoc protons. 
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Appendix 24: 1H NMR Fmoc-oxazole-OMe (9). 
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Appendix 25: COSY NMR Fmoc-oxazole-OMe (9). 
The signal appearing at δ 8.85 ppm (s, 1H; CH (oxazole)) in the 1H NMR spectrum 
revealed the formation of the oxazole ring 
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Appendix 26: 13C NMR Fmoc-oxazole-OMe (9). 
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Appendix 27: DEPT 135 NMR Fmoc-oxazole-OMe (9). 
 
Appendix 28: DEPT 90 NMR Fmoc-oxazole-OMe (9). 
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Appendix 29: 1H NMR Fmoc-oxazole-COOH (10). 
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* Peaks at 1.24, 2.01 and 4.10 ppm due to EtOAc solvent. 
The NMR spectrum of the deprotected Fmoc-oxazole-COOH was confirmed by the 
disappearance of the methyl ester proton that was at 3.81 ppm (s, OCH3) in starting 
material Fmoc-oxazole-OMe. 
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Appendix 30: 1H NMR Fmoc-dioxazole-OMe (11). 
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Appendix 31: COSY NMR Fmoc-dioxazole-OMe (11). 
The two signals at 8.50 and 8.42 ppm represents to the two protons from the oxazole 
rings. 
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Appendix 32: 13C NMR Fmoc-dioxazole-OMe (11). 
 
 
Appendix 33: DEPT 135 NMR Fmoc-dioxazole-OMe (11). 
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Appendix 34: 1H NMR Fmoc-dioxazole-COOH (12). 
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• Peaks at 1.24, 2.01 and 4.10 ppm for EtOAc solvent. 
The disappearance of the methyl ester signal conformed the deprotection of methyl ester 
group. 
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Appendix 35: 1H NMR H2N-oxazole-OMe (13). 
* Peaks at 0.93 and 1.27 ppm due to hexane solvent 
*Peaks at 2.11 ppm due to acetone solvent 
The disappearance of the Fmoc protons peaks conformed the Fmoc deprotection step. 
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Appendix 36: 1H NMR Fmoc-tetraoxazole-OMe (14). 
• Peaks at 0.88 and 1.26 ppm due to hexane 
• Peak at 2.8 due to urea by-product 
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Appendix 37: COSY NMR Fmoc-tetraoxazole-OMe (14). 
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Appendix 38: 13C NMR Fmoc-tetraoxazole-OMe (14). 
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Appendix 39: DEPT 135 NMR Fmoc-tetraoxazole-OMe. 
 
Appendix 40: DEPT 90 NMR Fmoc-tetraoxazole-OMe (14). 
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Appendix 41: 1H NMR Fmoc-trioxazole-OMe (15). 
• Peaks at 0.88 and 1.26 ppm due to hexane 
• Peak at 2.1 ppm due to acetone 
• Peak at 2.8 due to urea by-product 
 
		










	










	



































	
























	




	


















	



	










	














	

























	




	


	

	





	



















	


	





















	

	



	





	


	





	



	






	



	




















3x2 
3x1 
* 
* 
* 
3x3,7,11 
6 3x4 
5 
8,2x10 
3x9 
O
NH
N
O
O
Si
H
N
O
O
N
O
H
N
O
N
O
O
O O
Si Si
1 2 3
4
5
6
7
8
9
10
4'
3'
2
1
9'
10'
4''
3''
2
1
9''
15
O 11
					
















		





		







	








	








	





	

	



	








	








	
	


	


	


	


	


		
	









	



	  	   126	  
 
Appendix 42: 13C NMR Fmoc-trioxazole-OMe (15). 
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Appendix 43: 1H NMR Fmoc-trioxazole-COOH (16). 
* Peaks due to EtOAc solvent 
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Appendix 44:	  1H NMR H2N-tetraoxazole-COOH (18).	  
• Peaks at 4.32, 3.53, 2.95, 1.70, 1.46 ppm due to DBU base  
• Peaks at 7.69 – 7.60 (m, 4H), 7.39 (m, 4H) due to by-product from Fmoc cleavge 
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Appendix 45: 1H NMR tetraoxazole macrocyclic peptide with TBS groups (19). 
 
* Peak at 1.28 and 3.93 ppm are unknown  
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Appendix 46: 1H NMR Boc-Cys(t-Bu)-OH-Ser-OMe (20). 
* Peak at 2.8 ppm due to urea by-product 
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Appendix 47: 13C NMR Boc-Cys(t-Bu)-OH-Ser-OMe (20). 
* Peaks at 159.91, 39.44 from urea by-product. 
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Appendix 48: 1H NMR Boc-oxazole-OMe (21). 
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Appendix 49: 13C NMR Boc-oxazole-OMe (21). 
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Appendix 50: 1H NMR Boc-oxazole-COOH (22). 
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Appendix 51: 13C NMR Boc-oxazole-COOH (22). 
 
• Peaks due to EtOAc and acetone solvents 
 
 
 
 
 
 
	












	










	




	

	




	
	















	







	



	











NHN OH
O
OS
O
O
22
1
2
3
4
5
6
7
8
9
10
11
7 
1 
* 
3 
2 
4 * 
6 
* 
9 
10 
5 
11  8 
	  	   137	  
 
Appendix 52: 1H NMR HCl.H2N-oxazole-OMe (23). 
 
		


















	
	















	

		
















		




























	


	








	


	











		







	











	
NH2N O
O
OS
23
1
2
3
HCl4
5
6 1 
2  2’ 
6 
3 
5 
	
	
























	


		




























	


	








	


	











		







	








	  	   138	  
 
Appendix 53: 13C NMR HCl.H2N-oxazole-OMe (23). 
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Appendix 54: 1H NMR Boc-dioxazole-OMe (24). 
* Peaks due to EtOAc solvent, t-Bu as a multiplet and the integration is higher than 18H 
because it is overlap with peak from EtOAc. 
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Appendix 55: 13C NMR Boc-dioxazole-OMe (24). 
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Appendix 56: 1H NMR Boc-dioxazole-COOH (25). 
• Peaks due to EtOAc solvent 
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Appendix 57: 13C NMR Boc-dioxazole-COOH (25). 
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Appendix 58: 1H NMR Boc-trioxazole-OMe (26). 
 
		










	




	
	











	

	

	
















	















	




















	





	


	


	





















	



	




	



	

	
	




	













3x1 
5 
3x2 
8 
4,3  3’ 3’’ 
7 7’ 3x6 * 
26
S
HN
O
N
O
H
N
N
O HN
S
OO O
N
O
O
S
O
1
2
3
4
5
6
7
3'
2'
1
6'
7
3''
2''
1
6''
8

	







































































































































	  	   144	  
 
Appendix 59: 13C NMR Boc-trioxazole-OMe (26). 
• Peaks due to hexane 
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Appendix 60: 1H NMR Boc-trioxazole-COOH (27). 
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Appendix 61: 1H NMR Boc-tetraoxazole-OMe (28). 
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Appendix 62: 13C NMR Boc-tetraoxazole-OMe (28). 
* Peaks at 1.26, 2.05 and 4.12 ppm due to EtOAc in 1H NMR 
* Peak at 22.71ppm due to Hexane and at 60.25 ppm for EtOAc and at 53.89 ppm for 
DCM 
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Appendix 63: 1H NMR HCl.H2N-tetraoxazole-COOH (30). 
* Peaks at 1.18, 3.51ppm for diethyl ethe, at 1.8, 3.8 ppm for tetrahydrofuran, and at 3.66 
ppm due to dioxane 
* The singlet peak at 1.9 ppm might be from C(CH3)3Cl that came from t-Bu cleavage 
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